Joint Ecco 15 â 34

Joint ECCO 15 – 34th ESMO
Multidisciplinary Congress
BERLIN, 20-24 SEPtEMBER 2009
advaNCE PROgRaMME & CaLL fOR aBStRaCtS
www.ecco-org.eu
European Society
for Medical Oncology

ERBITUX – the choice of enhanced efficacy
• 1st line metastatic CRC – 1st predictive biomarker
Significant improvements in PFS and response rate in combination
with standard chemotherapy are optimized in patients with KRAS wild-type tumors1,2
• Locally advanced SCCHN
Significantly prolongs survival in combination with radiotherapy3
Merck Serono Oncology | Combination is key
ERBITUX (cetuximab) abbreviated prescribing information. NOTE: Before prescribing ERBITUX, please consult the full prescribing information. Presentation: *ERBITUX 2 mg/ml solution for infusion. Each glass vial contains 50 ml. Excipients:
Sodium dihydrogen phosphate, disodium phosphate, sodium chloride, water for injections. *ERBITUX 5 mg/ml solution for infusion. Each glass vial contains 10 ml, 20 ml, 50 ml or 100 ml. Not al vial sizes may be marketed. Excipients: sodium
chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide, water for injections. Indications: Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer (mCRC)
in combination with chemotherapy, or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. Treatment of patients with local y advanced squamous cell cancer of the head
and neck (SCCHN) in combination with radiation therapy. Dosage and administration: Administer ERBITUX once a week. Very ﬁ rst dose 400 mg/m2 infused over 120 mins; subsequent doses 250 mg/m2 infused over 60 mins. Maximum infusion
rate must not exceed 10 mg/min. Administration must be supervised by a physician experienced in antineoplastic therapy. Closely monitor the patient throughout the infusion and for at least 1 hour afterwards. Resuscitation equipment must
be ensured. Prior to ﬁ rst infusion patients must receive premedication with an antihistamine and a corticosteroid; premedication recommended for al subsequent infusions. *ERBITUX 2 mg/ml: Administer intravenously via in-line ﬁ ltration with
an infusion pump, gravity drip or a syringe pump. *ERBITUX 5 mg/ml: Administer intravenously with an infusion pump, gravity drip or a syringe pump. mCRC: Administer ERBITUX ﬁ rst and do not administer chemotherapeutic agents earlier than
1 hour after the end of the ERBITUX infusion. ERBITUX should be continued until progression of the underlying disease. SCCHN: Start ERBITUX therapy one week before radiation therapy and continue until the end of the radiation period.
Special Populations: No dose adjustment required in the elderly (experience limited in patients older than 75 years). Safety and efﬁ cacy in children not established. Only patients with adequate renal, hepatic and hematological parameters
have been investigated. Contraindications: Known severe hypersensitivity (grade 3 or 4) reactions to ERBITUX. Contraindications for concomitantly used chemotherapeutic agents or radiation therapy must be considered. Special warnings and
precautions: Infusion-related reactions: Severe infusion-related reactions to ERBITUX have been reported. They occur usual y during the ﬁ rst infusion and up to 1 hour after the end of infusion, but may occur after several hours or with subsequent
infusions. Occurrence of a severe infusion-related reaction requires immediate and permanent discontinuation of ERBITUX and may necessitate emergency treatment. Decrease infusion rate if mild or moderate infusion-related reaction occurs
and use lower rate in all subsequent infusions. Closely monitor patients with reduced performance status and pre-existing cardio-pulmonary disease. Skin reactions: Interrupt treatment if patient experiences a severe skin reaction (≥grade 3 NCI-
CTC). Only resume if reaction resolves to grade 2. With second or third occurrence of severe skin reactions, resume at lower dose (200 mg/m2 after second occurrence, 150 mg/m2 after third occurence) only if reaction resolves to grade 2. A fourth
occurrence of severe skin reaction, or failure to resolve to grade 2 during interruption, requires permanent discontinuation of ERBITUX. Respiratory disorders: Individual cases of interstitial lung disorders of unknown causal relationship to ERBITUX
have been reported. If interstitial lung disease is diagnosed, ERBITUX must be discontinued and patient be treated appropriately. Electrolyte disturbances: Severe hypomagnesaemia has been observed. Hypomagnesaemia is reversible following
discontinuation of ERBITUX. Hypokalaemia as a consequence of diarrhea may develop. Determination of serum electrolyte levels is recommended prior to and periodical y during ERBITUX treatment. Electrolyte repletion is recommended, as appropriate.
Pregnancy and lactation: Only use during pregnancy or as woman not employing adequate contraception if the potential beneﬁ t justiﬁ es potential risk to fetus. Breast-feeding during treatment with ERBITUX and for 2 months after the last dose
is not recommended. Undesirable effects: Very common (≥1/10): skin reactions (mainly as acne-like rash and/or pruritus, dry skin, desquamation, hypertrichosis, or nail disorders, single cases of skin necrosis), hypomagnesaemia, mild or moderate
infusion-related reactions (such as fever, chil s, dizziness, or dyspnoea), mild to moderate mucositis, which may lead to epistaxis, increase in liver enzyme levels. Common (≥1/100, <1/10): headache, conjunctivitis, diarrhea, nausea, vomiting, fatigue,
anorexia, which may lead to weight decrease; severe infusion-related reactions, in rare cases with fatal outcome, some may be anaphylactoid/anaphylactic in nature (including bronchospasm, urticaria, hypotension, loss of consciousness, or
shock); in rare cases, angina pectoris, myocardial infarction, or cardiac arrest. Uncommon (≥1/1000, <1/100): blepharitis, keratitis, deep vein thrombosis, pulmonary embolism. Frequency not known: superinfection of skin lesions with subsequent
complications (e.g. cel ulitis, erysipelas, staphylococcal scalded skin syndrome, or sepsis). In combination with local radiation therapy of the head and neck area, additional undesirable effects were those typical of radiation therapy (such as mucositis,
radiation dermatitis, dysphagia or leucopenia, mainly as lymphocytopenia). Reporting rates of severe acute radiation dermatitis, mucositis, late radiation-therapy related events were slightly higher in combination with cetuximab. Interactions: In
combination with infusional 5-ﬂ uorouracil, frequency of cardiac ischaemia including myocardial infarction and congestive heart failure as well as the frequency of hand-foot syndrome were increased. Marketing Authorization Holder: Merck
KGaA, 64271 Darmstadt, Germany. Licence number (EMEA): EU/1/04/281/001-005. General classiﬁ cation for supply: Medicinal product subject to medical prescription. Date of Revision: July 2008. Merck KGaA, 64271 Darmstadt, Germany, Tel: +49
(0)6151 72-0, ERBITUX is a trademark of ImClone Systems Incorporated used under license by Merck KGaA, Darmstadt, Germany. *Please contact your local Merck Serono afﬁ liate regarding the availability of the speciﬁ c formulation in your country.
CRC, colorectal cancer; KRAS, a gene encoding a small GTPase that passes on a growth signal in the epidermal growth
factor receptor signaling pathway; PFS, progression-free survival; SCCHN, squamous-cell carcinoma of the head and neck
1. Van Cutsem et al. KRAS status and efﬁ cacy in the ﬁ rst-line treatment of patients with metastatic colorectal cancer treated
with FOLFIRI with or without cetuximab: The CRYSTAL experience. ASCO Annual Meeting 2008: Abstract 2.
2. Bokemeyer et al. KRAS status and efﬁ cacy of ﬁ rst-line treatment of patients with metastatic colorectal cancer with FOLFOX
with or without cetuximab: The OPUS experience. ASCO Annual Meeting 2008: Abstract 4000.
3. Bonner et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
N Engl J Med 2006; 354: 567–78.

ECCO 15 – ESMO 34
3
ECCO 15 – ESMO 34: Save the dates
Early Rate Registration Closes (receipt of payment)
31 March 2009
abstract Submission Closes
29 april 2009
fellowship grant application Closes
29 april 2009
Regular Rate Registration Closes (receipt of payment)
3 august 2009
housing Reservation Closes
15 august 2009
ECCO 15 – ESMO 34: Secretariat & venue
Congress Secretariat
c/o ECCO – the European CanCer Organisation
avenue E. Mounier 83
B-1200 Brussels
Belgium
tel: +32 2 775 02 01
fax: +32 2 775 02 00 / +32 2 775 02 45
Email: berlin09@ecco-org.eu
www.ecco-org.eu
Congress Venue
ICC Berlin - Internationales Congress Centrum
Messedamm 22
d-14055 Berlin
germany
tel: +49 30 3038 30 00
fax: +49 30 3038 30 30
www.icc-berlin.de
Exhibition
the ECCO 15 – ESMO 34 Exhibition represents an essential and integral element of the Congress,
providing participants with an excellent platform for networking as well as perfect opportunity
to gain insight into cutting edge technology, latest healthcare solutions and services within the
oncology field.
for information about sponsorship and exhibition opportunities please contact Bruno de Man,
Email: bruno.deman@ecco-org.eu, tel: +32 2 775 02 04.
to download the Invitation to Industry brochure and view the exhibition
floor plan visit: www.ecco-org.eu.
Accreditation for Continuous Medical Education (cme)
application for accreditation has been submitted
to the accreditation Council of Oncology in Europe (aCOE).

table of Contents
Letter of Welcome
5
ECCO – ESMO acknowledgement
6
Congress Committees
7
Scientific Programme

tracks and Chairs
8

Programme at a glance
9

detailed advance Programme
14
Call for abstracts
32

abstract Policies & Regulations
32

abstract Preparation & Submission
32

abstract Selection Process
33

Late-Breaking abstracts – Policy & Regulations
34

Embargo Policy
34

topic Categories
35
Registration

Individual Registration
36

group Registration
37
fellowship grants & Educational awards
39
general Information
40
hotel accommodation & tours
42
Contact Us
45
Registration form
47
accommodation form
49

ECCO 15 – ESMO 34
5
Letter of Welcome
LE
tt
ER O
the joint ECCO 15 – 34th ESMO Multidisciplinary Congress
interplay between the disciplines and individual tumour
f
in Berlin 20 - 24 September 2009, will not only build on the
types.
WEL
successes of the former ECCO and ESMO conferences, but
C
OME
also represents a major step forward in attracting the best
ECCO 15 – ESMO 34: New directions, new tracks
abstracts describing new ideas and practice changing data
from early clinical trials to multicentre Phase III trials.
• Oncopolicy is a new track for 2009. It has been
introduced to help strengthen European policy on cancer
ECCO 15 – ESMO 34: Call for Abstracts, bringing
and ensure it remains at the top of the EU health and
cutting-edge data back to Europe
research policy agenda. Only through such a unified
approach will European oncology professionals best
ECCO 15 – ESMO 34 marks the beginning of a new era,
engage with policymakers to promote the interests of
a virtual turning point in capturing European data to be
cancer patients, those who care for them, and those
showcased and make the headlines for the first time at
without whose research there would be no advances in
ECCO-ESMO, the premier European cancer meeting. the
treatment and care.

results we want to see in Berlin are those that will have
• Patient Advocacy/Ethics has for the first time been
a direct impact on patients with cancer; change the course
fully integrated as a track within the core ECCO 15 –
of their disease either through prevention, earlier diagnosis
ESMO 34 Scientific Programme to provide a forum for
or better treatment by providing new insights and answers
discussion on current topical issues of mutual concern to
to the many unresolved challenges facing patients with
cancer patients, advocates and professionals as well as
cancer and those caring for them.
identifying future directions aimed at improving cancer
care across Europe.
With your abstracts, we aim to populate the Congress with

the very best discussions and more importantly, impact
• Oncology Nursing has also been combined into a
significantly on public health by building towards a unified
distinct track, allowing cancer nurses to follow all
and optimal system of cancer care throughout Europe.
sessions in the programme.

• The Young Oncologists Track has been integrated
to ensure maximum exposure for top quality abstracts
into the Scientific Programme for the very first time,
we have increased proffered paper slots and presidential
emphasising the importance of catering to the needs of
sessions. We have also revised our late-breaking abstract
our young physicians, practitioners and scientists who
submission policy to include exciting findings that will not
will be critical for the next generation of cancer research,
be available in time for regular abstract submission.
and treatment.
We trust that you will support our efforts by selecting
as a demonstration of your commitment to advancing
ECCO 15 – ESMO 34 as the definitive platform for ‘first
European cancer therapeutics and prevention, we look
outing’ data disclosure and exposure.
forward to receiving your data and to welcoming you to
what promises to be a mass gathering and celebration of
ECCO 15 – ESMO 34: A Scientific Programme of ‘firsts’
European basic, translational and clinical studies: ECCO 15 –
ESMO 34, Berlin, 20 - 24 September 2009.
ECCO 15 – ESMO 34 will continue the established tradition
of delivering the latest advances and insight in scientific
and clinical research, patient management and practice
alexander M.M. Eggermont
through an outstanding range of plenary sessions, teaching
ECCO President and Congress Chair
lectures, scientific and educational symposia, debates,
workshops, proffered paper sessions and so much more.
José Baselga
ESMO President
It is the ‘so much more’ for 2009 that will make this
Congress a meeting of exciting additions, some of which we
Chris twelves
would like to highlight:
Co-Scientific Chair (ECCO)
ECCO 15 – ESMO 34: Serving multidisciplinarity
fortunato Ciardiello
Co-Scientific Chair (ESMO)
the Scientific Programme, incorporating a record number
of 26 different tracks devised by over 100 leading experts,
Peter M. Schlag
will serve multidisciplinarity by guaranteeing the necessary
National Organising Committee Chair

6
ECCO – ESMO acknowledgement
ECCO – the European Cancer Organisation and ESMO – the European Society for Medical Oncology would gratefully like to
acknowledge the vital support, willing and collaboration of all the other ECCO Member Societies, without which the joint
ECCO-ESMO Multidisciplinary Congresses would not be possible:
Breast International
European association
European association of
European association of
group (BIg)
for Cancer Research (EaCR)
Nuclear Medicine (EaNM)
Neuro-Oncology (EaNO)
European association
European group for Blood and
association of European
European Oncology
of Urology (EaU)
Marrow transplantation (EBMt)
Cancer Leagues (ECL)
Nursing Society (EONS)
European Organisation for Research
European Society of
European School
European Society of Oncology
and treatment of Cancer (EORtC)
gynaecological Oncology (ESgO)
of Oncology (ESO)
Pharmacy (ESOP)
European Society of Surgical
European Society for therapeutic
the European Breast Cancer
the European Prostate Cancer
Oncology (ESSO)
Radiology and Oncology (EStRO)
Coalition (EUROPa dONNa)
Coalition (Europa Uomo)
European Society of Skin Cancer
European Society of Breast Cancer
flims alumni Club (faC)
Myeloma Euronet
Prevention (EUROSKIN)
Specialists (EUSOMa)
Organisation of European
European Society for
International Union
Cancer Institutes (OECI)
Paediatric Oncology (SIOPE)
against Cancer (UICC)

ECCO 15 – ESMO 34
7
Congress Committees
C
ON
g
Organising Committee
RESS C
a.M.M. Eggermont (NL)
ECCO President and Congress Chair
OMMI
J. Baselga (ES)
ESMO President & ECCO Board Member
M. Baumann (dE)
President Elect, ECCO
tt
EES
a-L. Børresen-dale (NO)
treasurer, ECCO
C. twelves (UK)
Co-Scientific Chair (ECCO)
f. Ciardiello (It)
Co-Scientific Chair (ESMO)
P. M. Schlag (dE)
National Organising Committee Chair
Executive Scientific Programme Committee
a.M.M. Eggermont (NL)
ECCO President and Congress Chair
J. Baselga (ES)
ESMO President
C. twelves (UK)
Co-Scientific Chair (ECCO)
f. Ciardiello (It)
Co-Scientific Chair (ESMO)
Vice Chairs
R. Bernards (NL)
Basic Science
v. gregoire (BE)
Radiotherapy
C. van de velde (NL)
Surgery
P. M. Schlag (dE)
National Organising Committee
National Organising Committee
Chair: P. M. Schlag, Berlin
R. andreesen, Regensburg
K. höffken, Jena
M. Bamberg, tübingen
W.hohenberger, Erlangen
M. Baumann, dresden
C. huber, Mainz
C. Bokemeyer, hamburg
W. Jonat, Kiel
v. Budach, Berlin
C. von Kalle, heidelberg
M. dietel, Berlin
M. Kaufmann, frankfurt
h. döhner, Ulm
U. Keilholz, Berlin
B. dörken, Berlin
P. Lichter, heidelberg
g. Ehninger, dresden
K. Miller, Berlin
R. Engenhart-Cabillic, Marburg
M. Molls, München
M. flentje, Würzburg
d. Niederwieser, Leipzig
h.E. gabbert, düsseldorf
K. Possinger, Berlin
U. graeven, Mönchengladbach
W. Schmiegel, Bochum
M. hallek, Köln
h-J. Schmoll, halle
g. henze, Berlin
M. thomas, heidelberg
W. hiddemann, München
O.d. Wiestler, heidelberg

8
Scientific Programme: tracks and Chairs
Basic Science
v. Jendrossek (dE), Y. Yarden (IL)
Breast Cancer

– advanced disease
f. Cardoso (BE), g. von Minckwitz (dE)

– Early disease
E. Rutgers (NL), g. von Minckwitz (dE)
Cancer in the Elderly
M. aapro (Ch), h. Wildiers (BE)
Central Nervous System
R. Stupp (Ch)
diagnostic/Biomarkers
J. foekens (NL), M. Pierotti (It)
drug development
J.C. Soria (fR)
Epidemiology, Primary & Secondary Prevention
P. Boffetta (fR)
gastrointestinal Malignancies

– Colorectal Cancer
C. Punt (NL), J. tabernero (ES)

– Non Colorectal Cancer
J.f. Bosset (fR), J. tabernero (ES)
genitourinary Malignancies

– Prostate Cancer
B. Escudier (fR), t. Wiegel (dE)

– Other
B. Escudier (fR), Z. Kirkali (tR)
gynaecological Cancer
g. gitsch (dE), C. Sessa (Ch)
haematological Malignancies and Myeloma
M. hallek (dE), J. S. Miguel (ES)
head and Neck Cancer
J. Bourhis (fR), J. vermorken (BE)
Imaging
E. aboagye (UK)
Lung Cancer
R. Rosell (ES)
Melanoma and Skin Cancer
U. Keilholz (dE)
Oncology Nursing
S. faithfull (UK)
Oncopolicy
J. Celis (dK), a.M.M. Eggermont (NL)
Paediatric Oncology
K. Pritchard-Jones (UK)
Patient advocacy/Ethics
L. denis (BE)
Radiotherapy/Radiobiology
M. Baumann (dE)
Regulatory/trial Methodology/Pharmacy
d. Lacombe (BE), K. Meier (dE)
Sarcoma: Soft tissue and Bone
J-Y. Blay (fR), S. Sleijfer (NL)
Surgical Oncology
C. van de velde (NL)
Symptom Science
M. aapro (Ch), S. Kaasa (NO)
translational Research
Y. Yarden (UK), N. Zaffaroni (It)
Young Oncologists
S. di Cosimo (ES), O. Belvedere (UK)
for all the forthcoming programme announcements and to discover the many reasons for making
ECCO 15 – ESMO 34 your must attend meeting for 2009 bookmark: www.ecco-org.eu.

9
The Joint ECCO15 – 34th ESMO Multidisciplinary Congress 2009 at a Glance
PRO
g
R
(Pre) Registration Opening Hours
a
MME

D Saturday 19 September 2009
a
t a g
08.00 - 18.00
group registration & material pick up
L
15.00 - 18.00
Individual registration & material pick up
a
NCE

D Sunday 20 September 2009
08.00 - 21.00
Registration & material pick up

D monday 21 - thurSday 24 September 2009
07.30 - 18.00
Registration & material pick up
Opening Event
Sunday 20 September
19.00 – 21.45
all registered participants are invited to attend the opening event including entertainment provided by
the Max Raabe & Palast Orchester and a networking welcome reception.
for further details regarding the opening event we invite you bookmark the event website: www.ecco-org.eu
(select 'Congresses and conferences').
Scientific Programme Sessions (*)
Monday 21 September 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08.00 - 18.15
tuesday 22 September 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08.00 - 18.15
Wednesday 23 September 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08.00 - 18.15
thursday 24 September 2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08.00 - 14.30
(*) all timing subject to change, for updates on the programme please check the event website: www.ecco-org.eu

(select 'Congresses and conferences')
Corporate Satellite Symposia
during the joint ECCO 15 – ESMO 34 Multidisciplinary Congress a number of Satellite Symposia will take place.
for further details, please see page 40.

10
P
oster session I
09:00 - 12:00
P
oster session II
14:00 - 17:00

t
i
f
i
c

society
ation
session
siope
a
ward +
paediatric
fered papers
paediatric
s
c
i
e
n
symposium
paediatric
MON
teaching lecture
special session
ow to select a
New approaches to
clinical trial design
for rare tumours
SIOPE
Prof
a
d
v
a
n
c
e
s

i
n

f
e
r
t
i
l
i
t
y
preserv
for children and
adolescents
h
new drug in
paedatric oncology
.
d

a
Y 21 SEP
teaching lecture
special session
surgical oncol
t
surgical oncology
Image-guided
surgery
Management of
peritoneal disease
EMBER 2009

.

t
i
f
i
c
a
’s and
nursing
s
c
i
e
n
nursing
fered papers
basic science
v
el therapeutics
symposium
young oncol
–
teaching lecture
special session
MicroRN
t
h
e
i
r

a
n
t
a
g
o
n
i
s
t
s

a
s
no
P
oster discussion
Case-based: linking
symptom science
to practice
Prof

PRO
o

o
r

g
L
CL
R
d
y
t
i
f
i
c
a
i
a
a
t
o
l
o
g
i
c
a
l
MME
y of
i
n
g

c
h
e
m
fered papers
s
c
i
e
n
haematology
haematology
haematology
symposium
haematology
teaching lecture
special session
t
herap
Prof
S
e
c
o
n
d
a
r
y
l
e
u
k
a
e
m
f
o
l
l
o
w
radiotherap
New drugs and
n
o
v
e
l

t
h
e
r
a
p
u
t
i
c
s
f
o
r

h
a
e
m
malignancies
a
t a g

L

care
&
a

NCE
e
d

p
a
t
i
e
n
t
s
advocacy session
patients
patients
patients
debate
patients
ocacy in
advocacy session
teaching lecture
special session
o patient
P
atient groups -
meeting the
challenge of
sustainable funding
a
dv
practice
I
n
f
o
r
m
r
e
c
e
i
v
e

b
e
t
t
e
r
treatment
a
ccess to
clinical trials
d
a
d
v
o
c
a
c
y

g
r
o
u
p
s
r
e
p
r
e
s
e
n
t

t
h
e
patients?

t
i
f
i
c
cns
P
v
nursing
fered papers
u
n
o
t
h
e
r
a
p
y
s
c
i
e
n
symposium
head and neck
h
m
teaching lecture
l
i
n
i
c
a
l

r
e
l
e
v
a
n
c
e
special session
a
and audit in
C
of
Prof
I
m
a
n
d

v
a
c
c
i
n
a
t
i
o
n

f
o
r

malignant glioma
surgical oncology
Q
colorectal cancer
in Europe

and

t
i
f
i
c

t
i
f
i
c
s
c
i
e
n
symposium
regulatory
s
c
i
e
n
symposium

a
g
g
r
e
s
s
i
v
e
head and neck
e
t
a
s
t
a
t
i
c

n
e
c
k
head and neck
teaching lecture
special session
e
a
d

a
n
d

n
e
c
k
Methodology
a
n
d

r
e
g
u
l
a
t
o
r
y
aspects of
biotherapeutics
chemotherapeutics
M
nodal carcinoma of
unknown primary
h
cancer treatment:
h
o
w
should we be?

y

ention
t
i
f
i
c
t
i
f
i
c
nursing
y
, prev
s
c
i
e
n
symposium
nursing
nursing
s
c
i
e
n
symposium
nursing
teaching lecture
special session
a
re we assessing
what is important
for patients and
families?
S
ymptom clusters
in cancer therap
a
ssessment and
measurement in
cancer care
a
f
t
e
r

c
a
n
c
e
r
therap
an promotion

y

t
i
f
i
c
e
n
e
t
i
c
society session
estro
general
s
c
i
e
n
symposium
E
P
I
:

g
radiotherapy
radiotherapy
teaching lecture
adron therap
special session
E
N
h
Cancer treatment in
emerging countries
g
prediction of
radiation damage
o
u
r

t
i
f
i
c

t
i
f
i
c
ER2
xia
h
y
s
c
i
e
n
a
y

i
n

t
u
m
s
c
i
e
n
gu-prostate

a
g
e
n
t
s

f
o
r
symposium
basic science
symposium
radiotherapy
a
repair of
translational
R and
teaching lecture
e
w
special session
N
N
metastatic
prostate cancer
t
he hypo
p
a
t
h
w
progression and
therap
d
radiation response
R
e
s
i
s
t
a
n
c
e
mechanisms to
E
gf
inhibitors

y

t
i
f
i
c
lung
gu-other
s
c
i
e
n
gu-prostate
fered papers
symposium
gu-prostate
teaching lecture
special session
Lung cancer
screening
Prof
Bladder cancer in
the elderly - issues on
o
p
e
r
a
t
i
o
n

a
n
d

c
h
o
i
c
e
of chemotherap
Prostate cancer

iling
13:30
14:30
t
i
f
i
c
lung
lung
colorectal
fered papers
s
c
i
e
n
symposium
teaching lecture
enomic prof
e
n
e
t
i
c

a
b
b
e
r
a
t
i
o
n
s
g
of colorectal cancer
Prof
15:30 - 17:30
g
in lung cancer

edu
breast
chemo in
anced
colorectal
fered papers
symposium
colorectal
teaching lecture
Challenges of
neoadj.
breast cancer
Prof
15:30 - 17:30
S
ystemic treatment
of adv
colorectal cancer
t
i
a
l

edu
opening
breast
breast
fered papers
session i
p
r
e
s
i
d
e
n
16:15 - 18:15
symposium
l
i
n
i
c
a
l

r
e
l
e
v
a
n
c
e
Opening session
Prof
t
he platform
f
o
r

t
r
a
n
s
l
a
t
i
o
n
a
l
cancer research
C
o
f

t
r
i
p
l
e

n
e
g
a
t
i
v
e
b
r
e
a
s
t

c
a
n
c
e
r
concept
08:00
08:45
09:00
10:50
11:00
13:00
13:15
15:30
16:15
17:00
18:00

v
11
P
oster
P
oster
session III
session I
09:00 - 12:00
14:00 - 17:00

a

-
t
i
f
i
c
t
i
f
i
c
ation for
paediatric
s
c
i
e
n
symposium
paediatric
s
c
i
e
n
symposium
paediatric
ining treatment
oung people
teaching lecture
t
a
d
v
a
n
c
e
s

i
n

f
e
r
t
i
l
i
t
y
perserv
children with
cancer
R
ecent break
t
h
r
o
u
g
h
s

a
n
d

f
u
t
u
r
e
breakthroughs
R
ef
a
n
d

t
h
e

c
o
s
t

o
f

t
h
e
cure - lessons from
s
o
f
t

t
i
s
s
u
e

s
a
r
c
o
m
in y
UES

d

a

t
i
f
i
c
Y 22 SEP
ers
f
in
ers in
nursing
debate
fered papers
diagnostic
s
c
i
e
n
symposium
diagnostic
elopment
translational
a
replication
teaching lecture
N
d
proteins as
biomark
in cancer
Prof
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
that we should
a
b
a
n
d
o
n

r
o
u
t
i
n
e
embedding of
tumour tissues
in paraf
Biomark
e
a
r
l
y

c
l
i
n
i
c
a
l
dev
t

EMBER 2009

elderly
elderly
fered papers
nursing
regulatory
fered papers
teaching lecture
special session
B
i
o
l
o
g
y

o
f

c
a
n
c
e
r
and aging
Prof
Individualisation of
treatment based on
pharmacokinetics
and pharmaco-
genomics
Prof
–

PRO

g

t
i
f
i
c
R
t
imaging
t
i
f
i
c
a

debate
MME
s
c
i
e
n
elderly
s
c
i
e
n
elderly
haematology
symposium
haematology
symposium
haematology
teaching lecture
special session
a
llogeneic
transplantation
R
ole of PE
Breast cancer
in the elderly
Clinical
management
of the elderly
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
that watching and
waiting is still an
option in indolent
lymphomas
a
.
t a g

.

i
l
l

b
e
L
a

oice in
NCE
p
l
i
s
h
e
d

o
r
e

n
e
e
d

a

e
n
t

w
patients
patients
patients
advocacy
session
patients
ving cancer
debate
patients
teaching lect
h
y

w
teaching lecture
surgical oncol
a
n
c
e
r

i
n

t
h
e
Mission
a
c
c
o
m
work in progress -
l
a
p
a
r
o
s
c
o
p
i
c

v
s
o
p
e
n

c
o
l
o
r
e
c
t
a
l
surgery
advocacy session
t
he burden
of cancer
W
patient v
Europe
advocacy session
C
workplace
Impro
outcomes through
h
e
a
l
t
h
y

l
i
f
e
s
t
y
l
e
choices
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
that individualised
t
r
e
a
t
m
the future

t
i
f
i
c
cns
cns
cns
cns
debate
o
l
e
c
u
l
a
r
fered papers
s
c
i
e
n
symposium
a
r
k
e
r
s

a
r
e

h
e
l
p
f
u
l
estigating
v
el targets and
teaching lecture
R
e-irradiation in
brain tumours -
e
v
i
d
e
n
c
e
,
indications and
limitations
Prof
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
t
h
a
t

m
m
for selecting
t
h
e
r
a
p
i
e
s

f
o
r
malignant glioma
Inv
no
a
n
t
i
-
a
n
g
i
o
g
e
n
e
s
i
s
agents in brain
tumours
y

e
r
e
a
g
e

t
i
f
i
c

eacr
a

d
a
m
s
c
i
e
n
N

a
b
o
u
t

c
a
n
c
e
r
symposium
o
u
r
o
g
e
n
e
s
i
s
ou wanted to

c
e
l
l
s

b
u
t

w
society session
special session
basic science
basic science
edu symposium
translational
S
y
n
t
h
e
t
i
c

l
e
t
h
a
l
i
t
y
a
s

a

n
o
v
e
l

s
t
r
a
t
e
g
y
of cancer therap
t
h
e

d
response in
cancer: role in
t
u
m
and targeted
therapies
a
ll y
k
n
o
w
s
t
e
m
afraid to ask

y

t
i
f
i
c
t
i
f
i
c

e

nursing
s
c
i
e
n
symposium
nursing
nursing
s
c
i
e
n
symposium
nursing
nursing
teaching lecture
special session
special session
Cancer and
n
u
t
r
i
t
i
o
n

k
e
y
determinants
of quality of life
R
esearching
complex clinical
issues in
cancer care
P
alliativ
cancer care
Managing
emotional concerns
Case-based:
critical moments
in cancer therap

e

debate
alue of new
radiotherapy
fered papers
a
g
i
n
g

t
e
c
h
n
o
l
o
g
y
oncopolicy
t
tumours
head and neck
head and neck
teaching lecture
special session
special session
IS
t
he v
i
m
f
o
r

t
a
r
g
e
t

v
o
l
u
m
delineation
National cancer plans
surgical oncology
Management of
g
Prof
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
that bio radiation
can replace chemo-
radiation in head and
neck cancer

i
a
,

y
t
i
f
i
c
y

forum
gu-other
fered papers
a
g
e

a
f
t
e
r
s
c
i
e
n
symposium
radiotherapy
radiotherapy
oncopolicy
elopment:
teaching lecture
special session
Prof
v
ery late tissue
d
a
m
radiotherap
Biological imaging
f
o
r

a
d
a
p
t
i
v
e
radiotherap
Optimising drug
dev
i
s
s
u
e
s

f
o
r

a
c
a
d
e
m
industry and
regulatory bodies

in
h
i
c
h

i
s
t
i
f
i
c
anced
lung
esmo
fects of
e
n
t

f
o
r

e
a
r
l
y
C/rare tumours
s
c
i
e
n
(dMMR)
gu-prostate
symposium
colorectal
colorectal
icient mismatch
teaching lecture
society session
special session
special session
ef
Chest tumours/
NSCL
a
ward session
Side-ef
t
r
e
a
t
m
d
i
s
e
a
s
e

-

w
the best?
Locally-adv
rectal cancer
d
repair
colorectal cancer

13:30
14:30

a
S story
ond
lung
lung
ic issues
colorectal
fered papers
gu-prostate
ter relapse
teaching lecture
edu symposium
special session
t
he KR
and bey
Prof
Prostate cancer -
t
h
e
r
a
p
e
u
t
i
c

o
p
t
i
o
n
s
af
Specif
i
n

l
u
n
g

c
a
n
c
e
r
management

C?

o
d
a
l
i
t
y

anced
e
n
d
a
t
i
o
n
s
breast
lung
m
y for
u
l
t
i
m
debate
colorectal
fered papers
gu-prostate
teaching lecture
edu symposium
a
n

t
h
e
r
e

b
e
Bisphosphonates
for care and cure
Prof
C
generalised
r
e
c
o
m
f
o
r

m
treatment in
stage III NSCL
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
t
h
a
t

r
a
d
i
c
a
l

s
u
r
g
e
r
y
is better than
radical radiation
therap
locally-adv
prostate cancer
e

y

t
i
f
i
c

o
t
h
e
r
a
p
y
e

breast
keynote
breast
debate
breast
es that it is
highlights
fered papers
s
c
i
e
n
cle in cancer
a
r
d
s
,

l
a
t
e
symposium
Prof
t
a
r
g
e
t
i
n
g

t
h
e

c
e
l
l
cy
presidential ii
w
a
breaking and
best abstracts
t
argeted therap
in breast cancer
t
his house
believ
appropriate to giv
a
d
j
.

c
h
e
m
f
o
r

e
n
d
o
c
r
i
n
e
responsiv
tumours
08:00
08:45
09:00
11:00
11:15
12:00
12:30
14:30
14:45
16:45
17:00
18:00

v

v
I
12
P
oster
session
P
oster
session
09:00 - 12:00
14:00 - 17:00
.

t
i
f
i
c
t
i
f
i
c
debate
v
e outcomes
s
c
i
e
n
symposium
paediatric
paediatric
s
c
i
e
n
symposium
paediatric
ances in
WE
teaching lecture
surgical oncol
a
n update of
s
e
n
t
i
n
e
l

n
o
d
e
biopsy on
breast cancer
New imaging
a
p
p
r
o
a
c
h
e
s
to response
assessement in
childhood cancer
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
that teenage and
y
o
u
n
g

a
d
u
l
t

u
n
i
t
s
impro
a
dv
Leukaemia
d
.
.

.
.
NES

d
t
i
f
i
c

t
i
f
i
c
a
ymposium
C
O/EJC
Y 23 SEP
s
c
i
e
n
symposium
s
c
i
e
n
symposium
young oncol
young oncol
young oncol
young oncol
teaching lecture
special session
t
he challenge
of interacting
with patients
f
LIMS S
and EC
a
ward
Oncology
Societies: why?
I
n
n
o
v
a
t
i
o
n
s

i
n

e
a
r
l
y
clinical trials

a
t
EMBER 2009

t
i
f
i
c

t
i
f
i
c
s
c
i
e
n
imaging
sarcoma
s
c
i
e
n
sarcoma
basic science
symposium
symposium
cellence in
teaching lecture
special session
Chromatin
remodelling
and cancer
Molecular imaging
in cancer
Sarcoma orientated
networks of
ex
Europe II
S
p
e
c
i
a
l

t
h
e
r
a
p
i
e
s
f
o
r

s
p
e
c
i
a
l

s
a
r
c
o
m
subtypes

–

PRO

t
i
f
i
c

including
g
R
a
regulatory
s
c
i
e
n
symposium
o
l
e
c
u
l
a
r

b
i
o
l
o
g
y
bedside
MME
teaching lecture
symptom science
special session
a
ntiemetics -
state of the art
Special session on
regulatory issues
symptom science
S
ymptom
managament: from
m
to
pain and cachexia

a
.

.

P
v

t a g
t
i
f
i
c
ention
L
a
drug devel
elopment
drug devel
fered papers
s
c
i
e
n
symposium
NCE
epidemiology
ining optimal
epidemiology
teaching lecture
special session
ef
Pharmacokinetics
in oncology drug
dev
Prof
d
s
t
r
a
t
e
g
i
e
s

f
o
r

h
v
accination
Cancer prev
in Europe

a

i
l
l

t
i
f
i
c
i
c
ant
t
i
f
i
c
debate
debate
melanoma
s
c
i
e
n
symposium
melanoma
e
l
a
n
o
m
melanoma
s
c
i
e
n
symposium
melanoma
fered papers
regulatory
teaching lecture
ow to perform
u
r
r
e
n
t

a
v
e
n
u
e
s
h
t
r
a
n
s
l
a
t
i
o
n
a
l
research in
melanoma
C
in clinical trials
f
o
r

m
treatment
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
that adjuv
treatment should
be the standard
in stage II-III
melanoma
Prof
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
t
h
a
t

g
e
n
o
m
s
i
g
n
a
t
u
r
e
s

w
b
e

u
s
e
f
u
l

f
o
r
personalised
medicine

a
n
a
g
e
t
i
f
i
c
anced
esso
debate
gu-other
society session

t
o

m
s
c
i
e
n
o
r
a
d
i
o
t
h
e
r
a
p
y
symposium
alid option in
translational
teaching lecture
o
w
special session
I tract
Current treatment
of high risk
testis cancer
h
the patient who
presents with
s
t
a
g
e

I
v

c
o
l
o
r
e
c
t
a
l
cancer?
surgical oncology
S
e
n
t
i
n
e
l

n
o
d
e
s
t
a
g
i
n
g

a
n
d

c
l
i
n
i
c
a
l
implications in
g
t
argeting tumour
cell signalling
non-colorectal
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
that upfront
c
h
e
m
is a v
locally-adv
pancreatic cancer

t
i
f
i
c
EONS
nursing
s
c
i
e
n
symposium
nursing
nursing
nursing
aluation of
ergence within
teaching lecture
iv
special session
society session
special session
Ev
q
u
a
l
i
t
y

i
n
d
i
c
a
t
o
r
s
for cancer services
d
cancer nursing
roles
Using evidence-
b
a
s
e
d

c
a
n
c
e
r
nursing practice
t
h
e

f
u
t
u
r
e

i
s
ambulatory care
Case-based:
leadership and
management

e

.

y for
t
i
f
i
c

y
debate
a
s
t
e

o
f

t
i
m
s
c
i
e
n
symposium
radiotherapy
t

a
n
d

b
i
o
l
o
g
i
c
a
l
R
fered papers
drug devel
translational
elopment
radiotherapy
teaching lecture
special session
I
M
approaches in
radiotherap
prostate cancer
non-colorectal
Prof
Imaging in drug
dev
t
argeting in
radiotherap
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
t
h
a
t

P
h
a
s
e

I
I

t
r
i
a
l
s
a
r
e

a

w
and money

y in

c
e
l
l
s

t
i
f
i
c

fered papers
s
c
i
e
n
symposium
gu-other
C and how to
radiotherapy
translational
teaching lecture
gynaecological
gynaecological
special session
a
n
c
e
r

s
t
e
m
fects of therap
special session
Endometriosis
and cancer
Prof
C
and radiation
resistance
What are the side-
ef
mRC
handle them?
Circulating
tumour cells

C
t
i
f
i
c
t
i
f
i
c
lung
a
c
e
u
t
i
c
a
l
lung
s
c
i
e
n

symposium
oncopolicy
s
c
i
e
n
symposium
teaching lecture
i
g
h

l
e
v
e
l
special session
gynaecological
a
l
i
g
n
a
n
t

p
l
e
u
r
a
l
t
reatment of limited
disease-SCL
h
p
h
a
r
m
forum
recommendations
Immune system and
o
v
arian cancers
Management of
m
mesothelioma

–
asco
t
i
f
i
c
joint
v
ersies in
debate
es that
colorectal
symposium
ecco
gu-other
s
c
i
e
n
symposium
colorectal

c
o
l
o
r
e
c
t
a
l
er metastases
radiotherapy
teaching lecture
S
c
r
e
e
n
i
n
g

f
o
r
c
o
l
o
r
e
c
t
a
l

c
a
n
c
e
r
,
where are we now?
Contro
individualised
management of
prostate cancer
special session
What is new in
the pathogenesis
o
f

u
r
o
t
h
e
l
i
a
l
cancer?
Liv
f
r
o
m
cancer
t
h
i
s

h
o
u
s
e
believ
hypofractionation
should be a
standard of care in
breast cancer

y

13:30
14:30

l
i
n
i
c
a
l
e
n
d
a
t
i
o
n
s
edu
breast
session

C
m
debate
t
KIs does
O
gu-other
e sense in
esmo special
symposium
ances in
teaching lecture
e
u
r
o
e
n
d
o
c
r
i
n
e
Late cardiac and
c
a
r
c
i
n
o
g
e
n
i
c

e
f
f
e
c
t
s
of radiotherap
E
S
M
r
e
c
o
m
session
a
dv
N
cancers
t
h
i
s

h
o
u
s
e

b
e
l
i
e
v
e
s
that sequential
use of
mak
renal cancer

s

t
i
f
i
c

edu

breast
lung
keynote
debate
es that
highlights
s
c
i
e
n
symposium
session III
presidential
a
r
d
s
,

l
a
t
e
symposium
basic science
n
c
o
g
e
n
e
s
I
s

c
y
t
o
t
o
x
i
c
treatment
outdated in
a
d
v
a
n
c
e
d

o
r

e
a
r
l
y
breast cancer
I
n
s
i
g
h
t
s

i
n
t
o

t
h
e
cancer cell, stem
c
e
l
l

i
n
t
e
r
f
a
c
e
t
h
r
o
u
g
h

s
y
s
t
e
m
biology
a
w
breaking and best
abstracts
O
revisited
t
h
i
s

h
o
u
s
e
believ
targeted
treatment should
b
e

u
s
e
d

i
n

a
l
l

c
a
s
e
s
with lung cancer
08:00
08:45
09:00
11:00
11:15
12:00
12:30
14:30
14:45
16:45
17:00
18:00

v
II
13
P
oster
session
09:00 - 12:00
.

y

-does it
t
i
f
i
c
ference?
s
c
i
e
n
symposium
p
h
a
d
e
n
e
c
t
o
m
I cancer
g
e a dif
symptom science
special session
t
Communication
crises in oncology
surgical oncol
L
y
m
for
mak
h
URS
.

.
.

d
a

t
i
f
i
c

Y
24 SEP
s
c
i
e
n
symposium
young oncol
elopment
young oncol
elopment
u
l
t
i
d
i
s
c
i
p
l
i
n
a
r
y
young oncol
teaching lecture
special session
a
r
e
e
r
Evidence-based
medicine:
dev
and implentation
of treatment
guidelines in
oncology
M
teams in
cancer care
C
dev
o
p
p
o
r
t
u
n
i
t
i
e
s

a
f
t
e
r
y
our degree
t
EMBER 2009

e
n
t

o
p
t
i
o
n
s
sarcoma

t
o

c
h
o
o
s
e

y
o
u
r
sarcoma
fered papers
sarcoma
teaching lecture
o
w
special session
h
t
r
e
a
t
m
for desmoids
Prof
Sarcomas in
adolescents
.
–

PRO

t
i
f
i
c
g
R
erse drug
a
s
c
i
e
n
symposium
regulatory
MME
ents
regulatory
teaching lecture
surgical oncol
special session
t
1
/
t
2

r
e
c
t
a
l

c
a
n
c
e
r
treatment
Monitoring and
management
of adv
ev
t
rial methodology

a

t a g
L
a
imaging

t
o

u
s
e
NCE
fered papers
imaging
basic science/
translational
teaching lecture
o
w
special session
h
f
u
n
c
t
i
o
n
a
l
imaging info for
r
a
d
i
o
t
h
e
r
a
p
y
planning?
Prof
Established and
emerging imaging
applications

o
f

c
e
r
v
i
c
a
l
t
i
f
i
c

s
p
e
c
i
a
l
a
c
e
u
t
i
c
a
l
s
v
eries in
o

s
c
i
e
n
session
symposium
e
s
m
epidemiology
teaching lecture
gynaecological
v
e
r
v
i
e
w
special session
O
v
accination
Current
challenges of
b
i
o
p
h
a
r
m
a
n
d

r
e
g
u
l
a
t
o
r
y
recommendations
Clinical
implications of
new disco
cancer genetics

t
i
f
i
c
nursing
cho-science:
s
c
i
e
n
symposium

t
a
r
g
e
t
s

f
o
r
basic science
teaching lecture
e
w
special session
Psy
where do we go
from here?
gynaecological
N
o
v
arian cancer
Mouse models of
cancer

t
i
f
i
c
ology
s
c
i
e
n
symposium
nursing
nursing
elopment of
special session
f
ertility and
s
e
x
u
a
l
i
t
y
:

t
h
e
dev
oncosex
f
uture trends and
EONS projects

h
a
t
’
s

a
p
p
r
o
a
c
h
e
s

f
o
r
v
el radiation
radiotherapy
radiotherapy
fered papers
radiotherapy
teaching lecture
special session
e
w
P
ersonalised
r
a
d
i
o
t
h
e
r
a
p
y
:

w
evidence-based?
Prof
N
evidence generation
of no
technologies

t
i
f
i
c
o
u
s

c
e
l
l
s
c
i
e
n
symposium
teaching lecture
non-colorectal
u
r
r
e
n
t

s
t
a
n
d
a
r
d
s
special session
C
and options in
the treatment of
s
q
u
a
m
esophageal cancer
non-colorectal
New directions
in the treatment of
gastric cancer
non-colorectal
E
n
d
o
s
c
o
p
i
c
treatment of
gastroesophageal
cancer

ention
ention of
edu
es in Europe
symposium
oncopolicy
oncopolicy
a
j
o
r

c
a
n
c
e
r
s
:

t
h
e
special session
r
u
g

a
n
d

l
i
f
e
s
t
y
l
e
Chemoprev
m
latest news
d
mediated prev
intiativ

.

edu
xicities of
breast
symposium
drug devel
v
el to
teaching lecture
Special features
o
f

l
o
b
u
l
a
r

c
a
n
c
e
r
implications for
management
Management and
interpretation of
no
molecular targeted
therapies

t
i
a
l
t
i
f
i
c
oung
breast
i
s
i
n
g

t
h
e
r
a
p
y
breast
session
highlights
s
c
i
e
n
symposium
ery y
p
t
i
m
special session
p
r
e
s
i
d
e
n
O
of v
women with early
breast cancer
L
o
c
o
r
e
g
i
o
n
a
l
control of breast
cancer
Closing session

presidential IV
Late breaking and
best abstracts
08:00
08:45
09:00
11:00
11:15
12:15
12:30
14:30

14
Detailed Advance Programme
General SeSSionS
Monday 21 September 2009
■
■ 14:45-16:45
Thursday 24 September 2009
educational Symposium: advances in
■
■ 09:00-10:50
■
■ 09:00-11:00
neuroendocrine tumours
opening Session
presidential Session IV
Chair: K. Oberg (Sweden)
Chair: A.M.M. Eggermont (The Netherlands)
Late breaking and best abstracts
Surgical aspects of
Opening addresses
neuroendocrine tumours
■
■ 12:30-14:30
Speaker: G. Åkerström (Sweden)
ECCO lifetime achievement award
presidential Session V
To be nominated
Lung tumours with neuroendocrine
differentiation
Closing session
drug discovery in the p53 pathway
Speaker: W.D. Travis (USA)
Speaker: D. Lane (United Kingdom)
Multiple endocrine neoplasia type 2 (MEN2)
Old drugs vs new drugs and new levels
Keynote lectureS
Speaker: K. Frank-Raue (Germany)
of complexity
Speaker: J.-P. Armand (France)
Role of radiopharmaceuticals in
Tuesday 22 September 2009
the diagnosis and treatment of
■
■ 13:30-14:30
neuroendocrine tumours (NEts)
■
■ 11:15-12:00
Speaker: I.J. Virgolini (Austria)
Special Session: Cancer treatment
Keynote Lecture
in emerging countries
targeting the cell cycle in cancer
Chair: J. Jassem (Poland)
PreSidential SeSSionS
Speaker: M. Barbacid (Spain)
facing increasing costs of cancer care:
Monday 21 September 2009
Polish experience
Wednesday 23 September 2009
Speaker: M. Krzakowski (Poland)
■
■ 13:15-16:00
■
■ 11:15-12:00
Management of breast cancer in
presidential Session I: the platform for
limited-resource countries
Keynote Lecture
translational cancer research
Speaker: A. Eniu (Romania)
Insights into the cancer cell, stem cell
Chair: A.M.M. Eggermont (The Netherlands)
discussion and roundup
interface through systems biology
Chair: J. Celis (Denmark)
Speaker: F. Buchholz (Germany)
Wednesday 23 September 2009
to be announced
Society SeSSionS
■
■ 09:00-11:00
Tuesday 22 September 2009
Joint eCCo – aSCo Symposium:
Monday 21 September 2009
■
■ 12:30-14:30
Controversies in individualised
management of prostate cancer
presidential Session II
■
■ 11:00-13:00
Chair: M. Baumann (Germany)
hamilton-fairley award Lecture
Society Session: european Society for
Chair: D. Blayney (USA)
therapeutic radiology and oncology
ECCO – Pezcoller award Lecture
(eStro)
Bioinformatics and gene discovery
Late breaking and best abstracts
Speaker: K. Pienta (USA)
Chair: V. Gregoire (Belgium)
active surveillance activities in Europe for
Wednesday 23 September 2009
Klaas breur award lecture
prostate cancer
Award Lecturer: P. Lambin (Belgium)
Speaker: C.H. Bangma (The Netherlands)
■
■ 12:30-14:30
emmanuel Van der Schueren
Watchful waiting in patients with
award lecture
presidential Session III
prostate cancer in USa
Award Lecturer: M. Coffey (Ireland)
Speaker: H. Ballentine Carter (USA)
ECCO Clinical Research award Lecture
Honorary member: W. Oyen (The Netherlands)
(Bio) Imaging guided selection and
Late breaking and best abstracts
Honorary member: P. Harari (USA)
application of personalised radiotherapy
Speaker: V. Khoo (United Kingdom)
Honorary member: A.L. Børresen-Dale
(Norway)

ECCO 15 – ESMO 34
15
a
d
v
a
NCE
P
RO
g
R
a
■
■ 11:00-13:00
the role of the medical oncologist
a randomised controlled trial of a
MME
Speaker: R. Glynne-Jones (United Kingdom)
symptom-orientated home care nursing
Society session: the european Society for
programme in patients with colorectal
paediatric oncology (SIope)
the role of the radiation oncologist
and breast cancer receiving oral
Speaker: V. Valentini (Italy)
Chair: K. Pritchard-Jones (United Kingdom)
chemotherapy
Chair: R. Ladenstein (Austria)
the role of the liver surgeon
Speaker: A. Molassiotis (United Kingdom)
Speaker: R. Adam (France)
award Lecture
Cancer supportive care - creating
Award Lecturer: To be announced
the role of the colorectal surgeon
opportunities within the dRg-system
Speaker: T. Wiggers (The Netherlands)
Speaker: P. Riemer-Hommel (Germany)
Proffered papers (6-8 papers)
Panel discussion
ambulatory cancer care for the older person
Tuesday 22 September 2009
Speaker: To be announced
■
■ 09:00-11:00
Concluding remarks
■
■ 09:00-11:00
eSmo Special Session: eSmo clinical
Speaker: To be announced
recommendations session
Society Session: european association for
Cancer research (eaCr)
Introduction
Thursday 24 September 2009
Chair: N. Pavlidis (Greece)
eaCr Lecture
Chair: R.A. Stahel (Switzerland)
■
■ 09:00-11:00
Session to be announced
Introduction
eSmo Special Session: Current challenges
Society session: european Society for
Speaker: N. Pavlidis (Greece)
of biopharmaceuticals and regulatory
medical oncology (eSmo) awards Session
recommendations
Chair: J. Baselga (Spain)
Renal cell cancer presentation
Speaker: To be announced
Introduction
ESMO presentation
Chair: J. Baselga (Spain)
Speaker: J. Baselga (Spain)
Renal cell cancer discussion
Chair: F. Ciardiello (Italy)
Speaker: To be announced
ESMO award presented by J. Baselga
targeted therapies in the oncology
Cancer pain presentation
ESMO Lifetime achievement award
setting: an overview
Speaker: To be announced
(supported by glaxoSmithKline)
Speaker: To be announced
presented by J. Baselga
Cancer pain discussion
Biosimilars: issues facing clinicians
Speaker: To be announced
ESMO Lifetime achievement award
Speaker: To be announced
Lecture
head and neck cancer presentation
Biosimilars: the industry perspective
Award Lecturer: To be announced
Speaker: To be announced
Speaker: To be announced
ESMO Exam (20th anniversary) and award
head and neck cancer discussion
approval strategies with new agents: the
presented by C. Bokemeyer (germany)
Speaker: To be announced
need to redefine comparator arms
Palliative Care designated Centre
Conclusions
Speaker: To be announced
accreditation
Speaker: R.A. Stahel (Switzerland)
approval strategies with new agents:
Speaker: R. Catane (Israel)
a regulatory perspective
■
■ 14:45-16:45
fellowship Programme and awards
Speaker: To be announced
Speaker: M. Piccart (Belgium)
Society session: european oncology
Conclusions
nursing Society (eonS)
Speaker: To be announced
Wednesday 23 September 2009
the future is ambulatory care
Chair: S. Kav (Turkey)
■
■ 09:00-11:00
Chair: To be announced
Society Session: european Society of
Presentation of the EONS distinguised
Surgical oncology (eSSo)
Merit award winner
how to manage the patient who presents
Speaker: S. Faithfull (United Kingdom)
with stage IV colorectal cancer
distinguished Merit award Lecturer
Chair: I. Taylor (United Kingdom)
Award Lecturer: To be nominated
ESSO award Lecture : Numbers and
Introduction
the dilemma
Speaker: S. Kav (Turkey)
Speaker: T. Wiggers (The Netherlands)

16
BaSic Science
BreaSt cancer - early and
advanced diSeaSe
Monday 21 September 2009
dNa damage responses as a barrier to
Monday 21 September 2009
tumourigenesis
■
■ 08:00-08:45
Speaker: J. Bartek (Denmark)
■
■ 08:00-08:45
teaching Lecture: micro rna’s and their
the dNa damage response: clues
teaching Lecture: Challenges of
antagonists as novel therapeutics
to carcinogenesis - and therapy
neoadjuvant chemotherapy in breast cancer
Speaker: To be announced
Speaker: Y. Shiloh (Israel)
Speaker: F. Andre (France)
■
■ 11:00-13:00
Exploiting cancer defects in
targeted therapy
■
■ 16:15-18:15
Scientific Symposium: the hypoxia
Speaker: T. Helleday (United Kingdom)
educational Symposium: Clinical
pathway in tumour progression
relevance of the triple negative breast
and therapy
dNa polymerases and cancer
cancer concept
Speaker: U. Hübscher (Switzerland)
Chair: J. Pouyssegur (France)
Chair: I. Ellis (United Kingdom)
Chair: V. Jendrossek (Germany)
Concluding remarks
Speaker: J. Bartek (Denmark)
Pathological definition of triple negative
Introduction
breast cancer
Speaker: J. Pouyssegur (France)
Wednesday 23 September 2009
Speaker: G. Viale (Italy)
Oxygen sensing, hIf hydroxylases and
the genetic basis of the concept
new cancer targets
■
■ 08:00-08:45
Speaker: L.J. van ‘t Veer (The Netherlands)
Speaker: W.G. Kaelin, Jr (USA)
teaching Lecture: Chromatin
Prognostic implications
Multitasking by pvhL in tumour
remodelling and cancer
Speaker: C. Caldas (United Kingdom)
suppression
Speaker: Z. Herceg (France)
Speaker: W. Krek (Switzerland)
therapeutic approach of early and
advanced triple negative breast cancer
hypoxia-inducible factor 1 in cancer
■
■ 14:45-16:45
Speaker: C. Jackisch (Germany)
pathogenesis and therapy
educational Symposium:
Speaker: G. Semenza (USA)
oncogenes revisited
Tuesday 22 September 2009
hypoxia signalling, metabolism
Chair: W. Gullick (United Kingdom)
and cancer
■
■ 08:00-08:45
Speaker: J. Pouyssegur (France)
the epidermal growth factor system of
ligands and receptors in cancer
teaching Lecture: bisphosphonates for
Concluding remarks
Speaker: W. Gullick (United Kingdom)
care and cure
Speaker: V. Jendrossek (Germany)
Speaker: J.-J. Body (Belgium)
RaS
Tuesday 22 September 2009
Speaker: To be announced
■
■ 14:45-16:45
the role of mtOR in cancer
Scientific Symposium: targeted therapy
■
■ 13:30-14:30
Speaker: S. Faivre (France)
in breast cancer
Special Session: Synthetic lethality
P53: balancing tumour suppression and
Chair: C. Zielinski (Austria)
as a novel strategy of cancer therapy
implications for the clinic
Chair: M. De Laurentis (Italy)
Speaker: V. Rotter (Israel)
Chair: R. Bernards (The Netherlands)
Introduction
hitting cancer where it hurts most: the
Thursday 24 September 2009
Speaker: M. De Laurentis (Italy)
RNai strategy to discover synthetic lethal
Optimising anti-hER2 therapy
interactions in cancer
■
■ 11:15-12:15
in early breast cancer
Speaker: R. Beijersbergen (The Netherlands)
Speaker: M. Piccart (Belgium)
Special Session: mouse models of cancer
Synthetic lethality - a novel strategy of
anti-hER2 therapy treatment
cancer therapy
Chair: A. Berns (The Netherlands)
after progression
Speaker: J. Downward (United Kingdom)
Identification of cancer genes and their
Speaker: G. von Minckwitz (Germany)
discussion and roundup
collaborative networks by large-scale
antiangiogenic drugs - quo vadis?
mutagenesis in tumour prone mice
Speaker: D. Miles (United Kingdom)
■
■ 14:45-16:45
Speaker: A. Berns (The Netherlands)
Combinations of endocrine agents and
Scientific Symposium: the dna damage
title: to be announced
new targeted drugs: where do we stand ?
response in cancer: role in tumourigenesis
Speaker: To be announced
Speaker: N. Harbeck (Germany)
and targeted therapy
discussion and roundup
Concluding remarks
Chair: J. Bartek (Denmark)
Speaker: C. Zielinski (Austria)
Chair: T. Helleday (United Kingdom)
Introduction
Speaker: T. Helleday (United Kingdom)

ECCO 15 – ESMO 34
17
a
■
■ 17:00-18:00
Epidemiology and prognosis of breast
Radiotherapy
d
v
cancer in very young population
Speaker: I. Kunkler (United Kingdom)
a
debate: this house believes that
NCE
Speaker: P. Tai (Canada)
it is appropriate to give adjuvant
Surgery
P
chemotherapy for endocrine
adjuvant therapy of very young women
Speaker: R.A. Audisio (United Kingdom)
RO
responsive tumours
with early breast cancer
g
Systemic therapy
R
Speaker: O. Pagani (Switzerland)
a
Moderator: F. Cardoso (Belgium)
Speaker: M. Extermann (USA)
MME
Speaker in favour: J. Crown (Ireland)
Strategies to preserve fertility in young
Concluding remarks
Seconder: M. Gnant (Austria)
breast cancer patients
Speaker: M. Aapro (Switzerland)
Speaker against: A. Di Leo (Italy)
Speaker: B. Gerber (Germany)
Seconder: M. Untch (Germany)
Child-bearing in breast cancer survivors
Speaker: N. Kroman (Denmark)
central nervouS SyStem
Wednesday 23 September 2009
Concluding remarks
Monday 21 September 2009
Speaker: O. Pagani (Switzerland)
■
■ 08:00-08:45
■
■ 13:30-14:30
teaching Lecture: Late cardiac and
■
■ 11:15-12:15
carcinogenic effects of radiotherapy
Special Session: Immunotherapy and
Special Session: Locoregional control of
Speaker: C. Correa (USA)
vaccination for malignant glioma
advanced breast cancer
Chair: P.Y. Dietrich (Switzerland)
■
■ 09:00-11:00
Chair: L. Cataliotti (Italy)
Introduction
Scientific Symposium: Is cytotoxic
the role of the surgeon
Speaker: P.Y. Dietrich (Switzerland)
treatment outdated in advanced or
Speaker: E.J.T. Rutgers (The Netherlands)
early breast cancer?
Clinical applications -
Locoregional control in metastasized
lessons from paediatrics
Chair: M. Colleoni (Italy)
breast cancer, the role of the radiation
Speaker: S. van Gool (Belgium)
Chair: V. Semiglazov (Russian Federation)
oncologist
Speaker: G. van Tienhoven (The Netherlands)
vaccination for glioma - results
Introduction
and experience
Speaker: M. Colleoni (Italy)
discussion and roundup
Speaker: A.F. Carpentier (France)
New cytotoxics - are there any and are
discussion and roundup
they still needed?
cancer in the elderly
Speaker: A. Awada (Belgium)
Tuesday 22 September 2009
targeted regimes without cytotoxics -
Tuesday 22 September 2009
are they ready for prime time?
■
■ 08:00-08:45
Speaker: F. Andre (France)
■
■ 08:00-08:45
teaching Lecture: re-irradiation
Role of maintenance chemotherapy
teaching Lecture: biology of cancer
in brain tumours - evidence, indications
in advanced breast cancer
and aging
and limitations
Speaker: P. Gascon (Spain)
Speaker: D. Van Heemst (The Netherlands)
Speaker: S. Short (United Kingdom)
Can we identify patients who do not
■
■ 13:30-14:30
benefit from adjuvant chemotherapy?
■
■ 13:30-14:30
Speaker: F. Cardoso (Belgium)
Special Session: breast cancer
debate: this house believes that
in the elderly
Concluding remarks
molecular markers are helpful
Speaker: V. Semiglazov (Russian Federation)
Moderator: E. Brain (France)
for selecting therapies for
malignant glioma
Elderly patients - a surgical perspective
Thursday 24 September 2009
Speaker: W. Jonat (Germany)
Moderator: R. Stupp (Switzerland)
Speaker in favour: M. Weller (Germany)
Elderly patients - a medical perspective
■
■ 08:00-08:45
Seconder: G. Reifenberger (Germany)
Speaker: H. Wildiers (Belgium)
Speaker against: M. Brada (United Kingdom)
teaching Lecture: Special features
discussion and roundup
Seconder: M.J. van den Bent (The Netherlands)
of lobular cancer implications for
management
■
■ 14:45-16:45
■
■ 14:45-16:45
Speaker: B.C. Pestalozzi (Switzerland)
Scientific Symposium: Clinical
Scientific Symposium: Investigating novel
■
■ 09:00-11:00
management of the elderly
targets and anti-angiogenic agents in
brain tumours
Scientific Symposium: optimising therapy
Chair: R.A. Audisio (United Kingdom)
of young women with early breast cancer
Chair: M. Aapro (Switzerland)
Chair: K. Lamszus (Germany)
Chair: M.J. van den Bent (The Netherlands)
Chair: M. Kaufmann (Germany)
Introduction
Chair: O. Pagani (Switzerland)
Speaker: R.A. Audisio (United Kingdom)
Introduction
Speaker: K. Lamszus (Germany)
Introduction
geriatric assessment
Speaker: M. Kaufmann (Germany)
Speaker: C. Terret (France)
anti-EgfR and anti-angiogenic therapy -
from mice to men
Speaker: K. Lamszus (Germany)

18
PtEN inhibition as a target
■
■ 17:00-18:00
Priorities in cancer prevention -
Speaker: I.K. Mellinghoff (USA)
the Eurocadet project
debate: this house believes that
Speaker: J.W. Coebergh (The Netherlands)
Novel molecular targets in the clinic
traditional phase II trials are a waste of
Speaker: U. Bogdahn (Germany)
time and money
frontiers of cancer
prevention research
Combining the adhesion pathway
Moderator: A. Awada (Belgium)
Speaker: L. Vatten (Norway)
inhibition with radiotherapy - from the
Speaker in favour: R. Kaplan (United Kingdom)
bench to the clinic
Seconder: M. Buyse (Belgium)
Concluding remarks
Speaker: E. Cohen-Jonathan-Moyal (France)
Speaker against: A. Sobrero (Italy)
Speaker: P. Boffetta (France)
Seconder: S.M. Bentzen (USA)
Concluding remarks
Chair: M.J. van den Bent (The Netherlands)
Thursday 24 September 2009
Thursday 24 September 2009
■
■ 11:15-12:15
diaGnoStic / BiomarKerS
■
■ 09:00-11:00
Special Session: Clinical implications
Tuesday 22 September 2009
educational Symposium: management
of new discoveries in cancer genetics
and interpretation of novel toxicities of
Chair: T. Bishop (United Kingdom)
molecular targeted therapies
■
■ 13:30-14:30
genetic factors in breast cancer
Chair: C. Twelves (United Kingdom)
debate: this house believes that we
Speaker: D. Easton (United Kingdom)
should abandon routine embedding
Skin toxicities of targeted therapies
genetic factors in lung cancer
of tumour tissues in paraffin
Speaker: S. Tejpar (Belgium)
Speaker: P.J. Brennan (France)
Moderator: R. Bernards (The Netherlands)
Renal toxicity
discussion and roundup
Speaker in favour: To be announced
Speaker: J. Carles (Spain)
Seconder: L.J. van ‘t Veer (The Netherlands)
hypertension and cardiotoxicity of
Speaker against: I. Ellis (United Kingdom)
GaStrointeStinal
molecularly targeted cancer agents
Seconder: Sir N. Wright (United Kingdom)
Speaker: L.L. Siu (Canada)
maliGnancieS -
colorectal cancer
■
■ 14:45-16:45
gastrointestinal toxicities of novel agents
in cancer therapy
Scientific Symposium: biomarkers in early
Speaker: G. Perlemuter (France)
Monday 21 September 2009
clinical drug development
Chair: J. Soria (France)
■
■ 08:00-08:45
ePidemioloGy,
Chair: E. Calvo (Spain)
Primary and Secondary
teaching Lecture: Genomic profiling
Introduction
Prevention
of colorectal cancer
Speaker: E. Calvo (Spain)
Speaker: P.G. Johnston (Ireland)
Overview of the biomarker problem
Wednesday 23 September 2009
■
■ 15:30-17:30
Speaker: D. Sidransky (USA)
educational Symposium: Systemic
the need for robust statistical designs
■
■ 13:30-14:30
treatment of advanced colorectal cancer
to bring biomarkers to the clinic
Special Session: defining optimal
Speaker: R. Simon (USA)
Chair: A. Sobrero (Italy)
strategies for hpV vaccination
Circulating tumour cells in early
Systematic treatment of advance
Chair: S. Franceschi (France)
clinical trials
colorectal cancer
Speaker: J. de Bono (United Kingdom)
Post-vaccine surveillance
Speaker: C.-H. Kohne (Germany)
Speaker: J. Dillner (Sweden)
genomics in early clinical trials
Chemotherapy - which drugs and when?
Speaker: L. Pusztai (USA)
Issues in combining cervical screening
Speaker: C.J.A. Punt (The Netherlands)
and vaccination
Clinical biomarkers and imaging
how to integrate biologicals in the
Speaker: J. Cuzick (United Kingdom)
for radiotherapy-induced cell death
continuum of care?
Speaker: M. Verheij (The Netherlands)
discussion and roundup
Speaker: J. Cassidy (United Kingdom)
Concluding remarks
Impact of molecular markers on
■
■ 14:45-16:45
Speaker: J. Soria (France)
treatment selection
Scientific Symposium: Cancer prevention
Speaker: E. Van Cutsem (Belgium)
in europe
druG develoPment
New approaches and targets
Chair: J.W. Coebergh (The Netherlands)
Speaker: J. Tabernero (Spain)
Wednesday 23 September 2009
Chair: P. Boffetta (France)
discussion
Introduction
■
■ 08:00-08:45
Speaker: J.W. Coebergh (The Netherlands)
Tuesday 22 September 2009
teaching Lecture: pharmacokinetics in
the causes of cancer
oncology drug development
Speaker: P. Boffetta (France)
■
■ 08:00-08:45
Speaker: C.H. Takimoto (USA)
Closing the cancer gap in Europe
teaching Lecture: the KraS story
Speaker: W. Zatonski (Poland)
and beyond
Speaker: P. Laurent Puig (France)

ECCO 15 – ESMO 34
19
■
■ 14:45-16:45
Which staging method is optimal?
■
■ 11:15-12:15
a
Speaker: W.J.G. Oyen (The Netherlands)
d
Scientific Symposium: Locally-advanced
Special Session: endoscopic treatment of
v
a
rectal cancer
Systemic treatment
gastroesophageal cancer
NCE
Speaker: H.J. Schmoll (Germany)
Chair: L. Påhlman (Sweden)
Chair: J.R. Armengol - Miro (Spain)
P
RO
Chair: D. Sebag-Montefiorie (United Kingdom)
Multidisciplinary perspective
New endoscopic imaging techniques for
g
Speaker: G. Poston (United Kingdom)
R
Introduction
the detection of early lesions
a
MME
Speaker: L. Påhlman (Sweden)
Speaker: R. Kiesslich (Germany)
GaStrointeStinal
Rectal cancer staging: which
Multi-modality therapy for early Barrett’s
method is optimal?
maliGnancieS -
neoplasia
Speaker: R.G.H. Beets-Tan (The Netherlands)
non-colorectal cancer
Speaker: J. Bergman (The Netherlands)
Chemoradiation as neoadjuvant
discussion and roundup
treatment: which schedule is best?
Wednesday 23 September 2009
Speaker: D. Sebag-Montefiorie
Genitourinary
(United Kingdom)
■
■ 17:00-18:00
maliGnancieS - other
Late complications of local
debate: this house believes that upfront
multimodality treatment
chemoradiotherapy is a valid option
Monday 21 September 2009
Speaker: C.J.H. van de Velde (The Netherlands)
in locally-advanced pancreatic cancer
Quality control of rectal surgery, a must?
Moderator: J. Neoptolemos (United Kingdom)
■
■ 13:30-14:30
Speaker: P. Quirke (United Kingdom)
Speaker in favour: G. van Tienhoven
Special Session: bladder cancer in the
(The Netherlands)
downstaging of rectal cancer: is sphincter
elderly - issues on operation and choice
Seconder: V. Budach (Germany)
preservation the goal?
of chemotherapy
Speaker against: B. Chauffert (France)
Speaker: L. Påhlman (Sweden)
Seconder: I. Chau (United Kingdom)
Chair: R. De Wit (The Netherlands)
Concluding remarks
Surgery for bladder cancer in elderly
Speaker: D. Sebag-Montefiorie
Thursday 24 September 2009
patients: risk, benefit and selection
(United Kingdom)
of technique
■
■ 08:00-08:45
Speaker: A. Stenzl (Germany)
■
■ 17:00-18:00
teaching Lecture: Current standards and
Unfit patient(s)
Special Session: deficient mismatch repair
options in the treatment of squamous cell
Speaker: R. De Wit (The Netherlands)
(dmmr) in colorectal cancer
esophageal cancer
Radiotherapy view
Chair: E. Vilar (USA)
Speaker: C. Mariette (France)
Speaker: J. Dunst (Germany)
dMMR: always genetic and sometimes
■
■ 09:00-11:00
discussion and roundup
hereditary
Speaker: N. Hoogerbrugge (The Netherlands)
Scientific Symposium: new directions
in the treatment of gastric cancer
Wednesday 23 September 2009
Should patients with dMMR be treated
with chemotherapy?
Chair: J. Tabernero (Spain)
■
■ 08:00-08:45
Speaker: R. Labianca (Italy)
Chair: F. Lordick (Germany)
teaching Lecture: Current treatment of
discussion and roundup
Introduction
high risk testis cancer
Speaker: J. Tabernero (Spain)
Speaker: H.J. Schmoll (Germany)
Wednesday 23 September 2009
Changing epidemiology of gastric cancer -
influence on treatment strategies
■
■ 13:30-14:30
■
■ 08:00-08:45
and outcome
Special Session: What is new in the
Speaker: Y.-K. Kang (South Korea)
teaching Lecture: Screening for colorectal
pathogenesis of urothelial cancer?
cancer, where are we now?
Optimal initial work-up and surgical
Chair: T.F. Orntoft (Denmark)
Speaker: N. Arber (Israel)
treatment in 2009?
Speaker: C.J.H. van de Velde
hereditary factors in bladder cancer
■
■ 14:45-16:45
(The Netherlands)
Speaker: L.A. Kiemeney (The Netherlands)
Scientific Symposium: Liver metastases
Perioperative treatment - current
histopathological profile of bladder cancer
from colorectal cancer
standards and next steps
Speaker: A. Lopez-Beltran (Spain)
Speaker: P. Rougier (France)
Chair: B. Nordlinger (France)
genomic alterations in urothelial
Chair: G. Poston (United Kingdom)
Current chemotherapy options for
carcinoma subgroups
advanced disease
Speaker: M. Knowles (United Kingdom)
Introduction
Speaker: E. Van Cutsem (Belgium)
Speaker: B. Nordlinger (France)
discussion and roundup
Integration of targeted therapies
New surgical developments
Speaker: J. Tabernero (Spain)
Speaker: R. Adam (France)
Concluding remarks
Radiofrequency ablation, a new standard?
Speaker: F. Lordick (Germany)
Speaker: T.J.M. Ruers (The Netherlands)

20
■
■ 14:45-16:45
Prostate cancer: the bone paradigm...
■
■ 13:30-14:30
Speaker: B. Tombal (Belgium)
Scientific Symposium: What are the side-
Special Session: Immune system and
effects of therapy in mrCC and how to
drug resistance in metastatic PCa
ovarian cancers
handle them?
Speaker: I.F. Tannock (Canada)
Chair: G. Coukos (USA)
Chair: Z. Kirkali (Turkey)
Concluding remarks
harnessing the immune system
Chair: B. Escudier (France)
Speaker: K. Fizazi (France)
for ovarian cancer therapy
Introduction
Speaker: G. Coukos (USA)
Speaker: Z. Kirkali (Turkey)
Tuesday 22 September 2009
Clinical trials on immunotherapy
tyrosine kinase inhibitors (tKIs)
in ovarian cancer
■
■ 13:30-14:30
Speaker: T. Eisen (United Kingdom)
Speaker: H. Nijman (The Netherlands)
Special Session: Side-effects of treatment
mtOR inhibitors, bevacizumab
discussion and roundup
for early disease - which is the best?
Speaker: B. Escudier (France)
Chair: M. Wirth (Germany)
do combination and sequential therapies
Thursday 24 September 2009
have increased side-effects?
Surgery
Speaker: C. Porta (Italy)
Speaker: M. Wirth (Germany)
■
■ 08:00-08:45
Cytokines and vaccines
Radiotherapy
teaching Lecture: overview
Speaker: P. Mulders (The Netherlands)
Speaker: C. Parker (United Kingdom)
of cervical vaccination
Speaker: E. Joura (Austria)
adjusting therapy in the elderly patient
active surveillance
Speaker: S. Negrier (France)
Speaker: C.H. Bangma (The Netherlands)
■
■ 09:00-11:00
Concluding remarks
discussion and roundup
Scientific Symposium: new targets
Speaker: B. Escudier (France)
for ovarian cancer
■
■ 14:45-16:45
■
■ 17:00-18:00
Chair: N. Colombo (Italy)
educational Symposium: prostate cancer -
Chair: C. Sessa (Switzerland)
debate: this house believes that
therapeutic options after relapse
sequential use of tKIs does make sense
Introduction
Chair: T. de Reijke (The Netherlands)
in renal cancer
Speaker: N. Colombo (Italy)
Chair: T. Wiegel (Germany)
Moderator: B. Escudier (France)
Biology of tumour angiogenesis
treatment of local progression after
Speaker in favour: T. Eisen (United Kingdom)
and potential biomarkers of effects
radiotherapy
Seconder: J. Bellmunt (Spain)
Speaker: C. Ruegg (Switzerland)
Speaker: T. de Reijke (The Netherlands)
Speaker against: A. Ravaud (France)
Clinical experience with antiangiogenic
Seconder: P. Mulders (The Netherlands)
Salvage radiotherapy in patients with
targeting in ovarian cancer
persisting/rising PSa after radical
Speaker: M. Bookman (USA)
prostatectomy for prostate cancer
Genitourinary
Speaker: T. Wiegel (Germany)
Emerging new targets
maliGnancieS -
Speaker: S.B. Kaye (United Kingdom)
ProState cancer
hormonal treatment for progression
Speaker: K. Miller (Germany)
Molecular determinants of
acquired resistance
Monday 21 September 2009
Chemotherapy in men with hormone-
Speaker: S. De Jong (The Netherlands)
refractory prostate cancer
Speaker: R. De Wit (The Netherlands)
Concluding remarks
■
■ 08:00-08:45
Speaker: C. Sessa (Switzerland)
teaching Lecture: New agents for
■
■ 17:00-18:00
metastatic prostate cancer
debate: this house believes that
haematoloGical
Speaker: K. Fizazi (France)
radical surgery is better than radical
maliGnancieS and
radiation therapy for locally-advanced
■
■ 15:30-17:30
myeloma
prostate cancer
Scientific Symposium: prostate cancer
Moderator: J. Bellmunt (Spain)
Monday 21 September 2009
Chair: I.F. Tannock (Canada)
Speaker in favour: H. van Poppel (Belgium)
Chair: K. Fizazi (France)
Seconder: R. Miralbell (Switzerland)
■
■ 08:00-08:45
Speaker against: C. Parker (United Kingdom)
Introduction
Seconder: M. Graefen (Germany)
teaching Lecture: therapy of diffuse large
Speaker: I.F. Tannock (Canada)
cell lymphon (dLCL)
Changing definition of hormone refractory
Speaker: M. Pfreundschuh (Germany)
Speaker: K. Fizazi (France)
GynaecoloGical cancer
■
■ 13:30-14:30
advances in molecular understanding of
Wednesday 23 September 2009
prostate cancer
Special Session: Secondary leukaemia
Speaker: J. Schalken (The Netherlands)
following chemo or radiotherapy
■
■ 08:00-08:45
Chair: D. Grimwade (United Kingdom)
teaching Lecture: endometriosis and cancer
Speaker: To be announced

ECCO 15 – ESMO 34
21
Molecular pathogenesis and biology of
Role of fdg-PEt and PEt/Ct in treatment
Prognostic and predictive value
a
secondary leukaemias
planning of other haematological tumours
of head and neck cancer
d
v
Speaker: D. Grimwade (United Kingdom)
Speaker: L. Specht (Denmark)
Speaker: M.L. Gillison (USA)
a
NCE
Secondary leukaemia after
Role of PEt in clinical trials of novel
Concluding remarks
P
breast cancer
therapies in haematology
Chair: J.B. Vermorken (Belgium)
RO
Speaker: F. Lo-Coco (Italy)
Speaker: B. Cheson (USA)
g
R
a
Secondary leukaemia after
Concluding remarks
Tuesday 22 September 2009
MME
hodgkin's disease
Speaker: M.H. Dreyling (Germany)
Speaker: A. Engert (Germany)
■
■ 17:00-18:00
■
■ 17:00-18:00
discussion and roundup
debate: this house believes that
debate: this house believes that watching
bioradiation can replace chemoradiation
■
■ 15:30-17:30
and waiting is still an option in indolent
in head and neck cancer
lymphomas
Scientific Symposium: new drugs
Moderator: L. Licitra (Italy)
and novel therapeutic targets
Moderator: A. Lister (United Kingdom)
Speaker in favour: K.K. Ang (USA)
for haematological malignancies
Speaker in favour: M.H. Dreyling (Germany)
Seconder: J. Overgaard (Denmark)
Seconder: P. Solal-Celigny (France)
Speaker against: M.R. Posner (USA)
Chair: J.F. San Miguel (Spain)
Speaker against: M. Ghielmini (Switzerland)
Seconder: J.B. Vermorken (Belgium)
Chair: M. Hallek (Germany)
Seconder: E. Kimby (Sweden)
Introduction
Speaker: M. Hallek (Germany)
imaGinG
head and necK cancer
New drugs and novel therapeutic
Wednesday 23 September 2009
principles in multiple myeloma
Monday 21 September 2009
Speaker: J.F. San Miguel (Spain)
■
■ 09:00-11:00
tyrosine kinase inhibitors in
■
■ 08:00-08:45
Scientific Symposium: molecular imaging
myeloid malignancies
teaching Lecture: Clinical relevance of
of cancer
Speaker: A. Burnett (United Kingdom)
hpV in head and neck cancer
Chair: E. Aboagye (United Kingdom)
JaK-2 and its inhibitors for
Speaker: M.L. Gillison (USA)
Chair: R. Blasberg (USA)
myeloid neoplasias
Speaker: A. Tefferi (USA)
■
■ 13:30-14:30
Introduction
Speaker: E. Aboagye (United Kingdom)
hdaCs inhibitors for lymphoid neoplasias
Special Session: metastatic neck nodal
Speaker: M. Kirschbaum (USA)
carcinoma of unknown primary
Reporter gene imaging in cancer
Speaker: R. Blasberg (USA)
Novel drugs in CLL
Chair: M. Merlano (Italy)
Speaker: M. Hallek (Germany)
Imaging of the tumour microenvironment
diagnostic issues and treatment
Speaker: R.J. Gillies (USA)
Concluding remarks
Speaker: M. Merlano (Italy)
Speaker: J.F. San Miguel (Spain)
Life and death of the cancer
Radiation therapy
cell-PEt imaging of proliferation
Speaker: V. Gregoire (Belgium)
Tuesday 22 September 2009
and apoptosis
discussion and roundup
Speaker: E. Aboagye (United Kingdom)
■
■ 08:00-08:45
MR imaging of angiogenesis
■
■ 15:30-17:30
Speaker: G. Jayson (United Kingdom)
teaching Lecture: allogeneic
Scientific Symposium: head and neck
transplantation
Concluding remarks
cancer treatment - how aggressive
Speaker: G. Ehninger (Germany)
Speaker: R. Blasberg (USA)
should we be?
■
■ 09:00-11:00
Chair: J. Bernier (Switzerland)
Thursday 24 September 2009
Chair: J.B. Vermorken (Belgium)
Scientific Symposium: role of pet imaging
Introduction
■
■ 08:00-08:45
Chair: M. Pfreundschuh (Germany)
Speaker: J. Bernier (Switzerland)
Chair: M.H. Dreyling (Germany)
teaching Lecture: how to use functional
Local regionally advanced
imaging information for radiotherapy
Introduction
disease - non-surgical approaches
planning
Speaker: M. Pfreundschuh (Germany)
Speaker: J. Bourhis (France)
haematological oncology: new PEt
Chair: V. Khoo (United Kingdom)
Local regionally advanced disease -
tracers for imaging pathophysiology and
surgical approaches including
PEt/Ct
response
postoperative treatment
Speaker: V. Gregoire (Belgium)
Speaker: S. Reske (Germany)
Speaker: R. Knecht (Germany)
MRI
PEt imaging of non-hodgkin lymphoma:
New developments in
Speaker: A.L. Grosu (Germany)
defining methodologies for early
larynx preservation
prediction of response
Speaker: J.L. Lefebvre (France)
Speaker: C. Haioun (France)
Molecular markers
predicting outcome
Speaker: C. Boshoff (United Kingdom)

22
■
■ 11:15-12:15
■
■ 14:45-16:45
the role of surgery
Speaker: D. Waller (United Kingdom)
Special Session: established and emerging
educational Symposium: Can there be
imaging applications
generalised recommendations
Multidisciplinary perspective
for multimodality treatment in
Speaker: P. Baas (The Netherlands)
Chair: A.F. Scarsbrook (United Kingdom)
stage III nSCLC?
MRI: development in 3t and higher field
■
■ 17:00-18:00
Chair: J. Vansteenkiste (Belgium)
instruments
debate: this house believes that targeted
Speaker: A. Heerschap (The Netherlands)
the multidisciplinarity of stage III NSCLC
treatment should be used in all cases with
Speaker: J. Vansteenkiste (Belgium)
PEt-Ct: has sensitivity and specificity
lung cancer
improved for staging and
Surgical treatment of stage III non-small
Moderator: R. Stahel (Switzerland)
response monitoring?
cell lung cancer (NSCLC)
Speaker in favour: G. Giaccone (USA)
Speaker: G. von Schulthess (Switzerland)
Speaker: P. Van Schil (Belgium)
Seconder: J. Soria (France)
discussion and roundup
Radiotherapy for stage III non-small cell
Speaker against: M. Reck (Germany)
lung cancer
Seconder: C. Gridelli (Italy)
Speaker: F. Mornex (France)
lunG cancer
Chemotherapy
melanoma and SKin cancer
Monday 21 September 2009
Speaker: W. Eberhardt (Germany)
Conclusion
Wednesday 23 September 2009
■
■ 08:00-08:45
Speaker: J. Vansteenkiste (Belgium)
■
■ 08:00-08:45
teaching Lecture: Lung cancer screening
■
■ 17:00-18:00
teaching Lecture: how to perform
Radiological screening
Special Session: Specific issues in lung
translational research in melanoma
Speaker: R.J. Van Klaveren (The Netherlands)
cancer management
Speaker: A. Spatz (Canada)
Biomarkers aspects
Chair: C. Gridelli (Italy)
Speaker: L.M. Montuenga (Spain)
■
■ 09:00-11:00
how to approach oligometastatic disease -
Scientific Symposium: Current avenues
■
■ 15:30-17:30
is there a role for surgery?
in clinical trials for melanoma treatment
Speaker: W. Weder (Switzerland)
Scientific Symposium: Genetic aberrations
Chair: P. Lorigan (United Kingdom)
in lung cancer
Stereotactic high dose radiotherapy
Chair: U. Keilholz (Germany)
treatment of early stage NSCLC
Chair: R. Stahel (Switzerland)
Speaker: M. Flentje (Germany)
Introduction
Chair: G. Giaccone (USA)
Speaker: P. Lorigan (United Kingdom)
Which is the best treatment for non-
Introduction
small lung cancer patients with PS 2?
targeting immune checkpoints: CtLa-4
Speaker: R. Stahel (Switzerland)
Speaker: C. Gridelli (Italy)
and related molecules
the role of biomarkers in selecting
Speaker: U. Keilholz (Germany)
discussion and roundup
the right targeted agent to combine
Melanoma vaccines - quo vadis?
with chemotherapy
Speaker: G. Parmiani (Italy)
Speaker: G. Giaccone (USA)
Wednesday 23 September 2009
targeting vEgf: sorafenib, axitinib,
Molecular mechanisms of lung cancer
■
■ 08:00-08:45
bevacizumab and others
development - how to use our knowledge
Speaker: P. Lorigan (United Kingdom)
of molecular biology in more
teaching Lecture: treatment of limited
effective therapies
disease - small cell lung cancer
Novel agents in clinical development
Speaker: Y. Yarden (Israel)
Speaker: D. De Ruysscher (The Netherlands)
(including bcl-2 antisense)
Speaker: K. Flaherty (USA)
genetic aberrations as determinants
■
■ 14:45-16:45
of response to chemotherapy
Concluding remarks
Speaker: R. Rosell (Spain)
Scientific Symposium: the management of
Speaker: U. Keilholz (Germany)
malignant pleural mesothelioma
Egf receptors
■
■ 13:30-14:30
Speaker: F. Ciardiello (Italy)
Chair: D. Waller (United Kingdom)
Chair: P. Baas (The Netherlands)
debate: this house believes that adjuvant
Closing remarks
treatment should be the standard in stage
Speaker: G. Giaccone (USA)
Introduction
II-III melanoma
Speaker: D. Waller (United Kingdom)
Tuesday 22 September 2009
Moderator: P. Patel (United Kingdom)
Biology of mesothelioma
Speaker in favour: J. Kirkwood (USA)
Speaker: P.A. Zucali (Italy)
Seconder: A. Hauschild (Germany)
■
■ 08:00-08:45
Chemotherapy
Speaker against: To be announced
teaching Lecture: Chest tumours /
Speaker: L. Paz-Ares (Spain)
Seconder: K.M. McMasters (USA)
non-small cell lung cancer / rare tumours
Radiotherapy
Speaker: E. Felip Font (Spain)
Speaker: C. Faivre-Finn
(United Kingdom)

ECCO 15 – ESMO 34
23
oncoloGy nurSinG
Monday 21 September 2009
■
■ 15:30-17:30
■
■ 13:30-14:30
a
d
Scientific Symposium: after cancer
Special Session: palliative cancer care
v
■
■ 08:00-08:45
a
therapy, prevention and promotion
NCE
Chair: S. Faithfull (United Kingdom)
teaching Lecture: are we assessing what is
Chair: S. Faithfull (United Kingdom)
P
important for patients and families?
Optimal approaches to persistent and
RO
Chair: F. Charnay-Sonnek (France)
Speaker: A. Richardson (United Kingdom)
chronic pain: new perspectives on an old
g
R
Introduction
problem
a
MME
■
■ 11:00-13:00
Speaker: S. Faithfull (United Kingdom)
Speaker: R. De wit (The Netherlands)
Scientific Symposium: Symptom clusters
Exercise for disease prevention and health
advanced disease: managing the complex
in cancer therapy
promotion in cancer survivors
journey of cancer recurrence
Speaker: K.S. Courneya (Canada)
Speaker: P. Larkin (Ireland)
Chair: S. Kav (Turkey)
Chair: To be announced
Managing late effects following
discussion and roundup
haematological malignancy and BMt
Introduction
Speaker: L. Bishop (United Kingdom)
■
■ 14:45-16:45
Speaker: S. Kav (Turkey)
assessment of young adult survivors
Scientific Symposium: managing
What’s new, what’s best in
needs: building an evidence-based late
emotional concerns
symptom management?
effects service
Speaker: C. Miaskowski (USA)
Chair: L. Fallowfield (United Kingdom)
Speaker: G. Levitt (United Kingdom)
Chair: J. Foubert (Belgium)
Evolving paradigms in the management of
Optimal approaches to post treatment
radiation side-effects
Introduction
recovery: multidisciplinary team working
Speaker: L. Sharp (Sweden)
Speaker: L. Fallowfield (United Kingdom)
Speaker: To be announced
the balance of endocrine therapy,
Management of depression for people
Concluding remarks
symptom burden and outcomes for
with cancer
Speaker: F. Charnay-Sonnek (France)
cancer survivors
Speaker: To be announced
Speaker: L. Fallowfield (United Kingdom)
Tuesday 22 September 2009
Clinical communication skills and coping,
Complex symptoms in advanced
the keys to helping patients
cancer: understanding multidisciplinary
Speaker: J. Foubert (Belgium)
■
■ 08:00-08:45
approaches
therapeutic decision-making in
Speaker: E. Ream (United Kingdom)
teaching Lecture: Cancer and nutrition
adolescents with cancer
key determinants of quality of life
Concluding remarks
Speaker: To be announced
Speaker: P. Ravasco (Portugal)
Speaker: To be announced
Communicating about illness: family
■
■ 09:00-11:00
nursing in oncology care
■
■ 13:30-14:30
Speaker: U. Östlund (Sweden)
Scientific Symposium: researching
Special Session: Case-based:
complex clinical issues in cancer care
Concluding remarks
linking symptom science to practice
Speaker: J. Foubert (Belgium)
Chair: S. Kav (Turkey)
Chair: U. Östlund (Sweden)
Chair: Y. Wengström (Sweden)
■
■ 17:00-18:00
Symptom management: a case study
Introduction
Speaker: C. Miaskowski (USA)
Special Session: Case-based:
Speaker: S. Kav (Turkey)
critical moments in cancer therapy
Symptom clusters: a case study
Nursing-sensitive outcomes:
Speaker: E. Ream (United Kingdom)
Chair: Sara Faithfull (United Kingdom)
what are they and should we be
discussion and roundup
measuring them?
targeted therapies and reactions
Speaker: D. Doran (Canada)
to EgfR inhibitors
■
■ 13:30-14:30
Speaker: A. Margulies (Switzerland)
Selecting appropriate outcome measures
Special Session: assessment
for exercise interventions in cancer
Controversies in anaemia:
and measurement in cancer care
survivors
risk of respite
Speaker: K.S. Courneya (Canada)
Speaker: L. Bishop (United Kingdom)
Chair: D. Kelly (United Kingdom)
design and methodological challenges in
discussion and roundup
developing cancer rehabilitation using
cancer-related quality of life research
appropriate assessment of need
Speaker: T. Kroll (United Kingdom)
Speaker: N. Doyle (United Kingdom)
Wednesday 23 September 2009
Patient-reported outcomes
Using evidence to assess complex
in cancer research
■
■ 08:00-08:45
symptoms: an education approach
Speaker: G. Velikova (United Kingdom)
in practice
teaching Lecture: evaluation of quality
Speaker: M. Krishnasamy (Australia)
Concluding remarks
indicators for cancer services
Speaker: Y. Wengström (Sweden)
Speaker: U. Wagner (Switzerland)
discussion and roundup

24
■
■ 09:00-11:00
■
■ 09:00-11:00
■
■ 17:00-18:30
Scientific Symposium: divergence within
Scientific Symposium: Fertility
Forum: optimising drug development:
cancer nursing roles
and sexuality: the development
issues for academia, industry and
of oncosexology
regulatory bodies
Chair: S. Faithfull (United Kingdom)
Chair: To be announced
Chair: S. Faithfull (United Kingdom)
Moderator: A.M.M. Eggermont
Chair: L. Incrocci (The Netherlands)
(The Netherlands)
Introduction
Speaker: S. Faithfull (United Kingdom)
Introduction
academia panel
Speaker: S. Faithfull (United Kingdom)
To be announced
Revision of professional roles: is this safe
and effective?
fertility understanding the options after
Industry panel
Speaker: M. Laurent (The Netherlands)
cancer treatment
To be announced
Speaker: L.R. Schover (USA)
Evidence of value-added benefit
Regulatory body panel
of specialist nursing roles?
talking about sex: identifying psycho-
To be announced
Speaker: D. Doran (Canada)
sexual concerns in the clinic
Speaker: I.D. White (United Kingdom)
developing the potential of community
Wednesday 23 September 2009
cancer nursing?
therapeutic approaches for sexual
Speaker: C. Kennedy (United Kingdom)
dysfunction in men treated for
■
■ 09:00-11:00
prostate cancer
advancing cancer nursing practice
Scientific Symposium: high level
Speaker: L. Incrocci (The Netherlands)
developing competencies for clinical
pharmaceutical forum recommendations
practice
Education and training staff: how to
To be announced
Speaker: To be announced
develop and integrate oncosexology?
Speaker: W.L. Gianotten (The Netherlands)
Concluding remarks
Thursday 24 September 2009
Speaker: To be announced
Concluding remarks
Speaker: L. Incrocci (The Netherlands)
■
■ 09:00-11:00
■
■ 13:30-14:30
■
■ 11:15-12:15
educational Symposium: Chemoprevention
Special Session: using evidence-based
of major cancers: the latest news
cancer nursing practice
Special Session: Future trends and
eonS projects
Chair: H. Senn (Switzerland)
Chair: Y. Wengström (Sweden)
Chair: To be announced
the rational and potential of
developing and sustaining evidence-
Chair: S. Kav (Turkey)
chemoprevention with special emphasis
based practice
on breast cancer
Speaker: To be announced
Prostate cancer and supportive care:
Speaker: A. Decensi (Italy)
European training needs analysis
Overcoming the barriers to making
Speaker: D. Kelly (United Kingdom)
Prostate cancer - chemoprevention
change in cancer services
Speaker: F.H. Schröder (The Netherlands)
Speaker: M. Krishnasamy (Australia)
What does the future cancer workforce
need to look like?
Colon cancer chemoprevention:
discussion and roundup
Speaker: S. Faithfull (United Kingdom)
ready for practice?
Speaker: N. Arber (Israel)
■
■ 17:00-18:00
discussion and roundup
Special Session: Case-based: leadership
■
■ 11:15-12:15
and management
oncoPolicy
Special Session: drug and lifestyle
Chair: J. Foubert (Belgium)
mediated prevention intiatives in Europe
Monday 21 September 2009
Measuring quality at a local level
Chair: J. Cuzick (United Kingdom)
Speaker: To be announced
■
■ 13:15-16:00
Obesity and overall cancer risk
Encouraging innovation
Speaker: A.G. Renehan (United Kingdom)
presidential Session I: the platform for
in clinical practice
translational cancer research
drug/lifestyle and breast cancer
Speaker: M. Krishnasamy (Australia)
prevention
Chair: A.M.M. Eggermont (The Netherlands)
discussion and roundup
Speaker: J. Cuzick (United Kingdom)
Chair: J. Celis (Denmark)
drug/lifestyle and colon cancer
Thursday 24 September 2009
To be announced
prevention
Speaker: F. Otto (Switzerland)
■
■ 08:00-08:45
Tuesday 22 September 2009
discussion and roundup
teaching Lecture: psycho-science: where
■
■ 09:00-10:00
do we go from here?
Speaker: L.G. Walker (United Kingdom)
Special Session: national cancer plans
To be announced

ECCO 15 – ESMO 34
25
Paediatric oncoloGy
Monday 21 September 2009
■
■ 09:00-11:00
are current tumour response criteria
a
relevant to the 21st century?
d
Scientific Symposium: recent
v
■
■ 08:00-08:45
Speaker: To be announced
a
breakthroughs and future directions
NCE
teaching Lecture: new approaches to
assessing changes in tumour metabolism
Chair: A. Biondi (Italy)
P
clinical trial design for rare tumours
using magnetic resonance spectroscopy
RO
Chair: J.R. Kowalczyk (Poland)
including childhood cancer
Speaker: A.C. Peet (United Kingdom)
g
R
Speaker: M. Le Deley (France)
Introduction
a
diffusion weighted imaging in the
MME
Speaker: A. Biondi (Italy)
evaluation of response in abdominal
■
■ 13:30-14:30
SIOP brain tumour trials
tumours
Special Session: advances in fertility
Speaker: F. Doz (France)
Speaker: O. Olsen (United Kingdom)
preservation for children and adolescents
SIOP Wilms tumour trials
assessing apoptosis in vivo using targeted
with cancer
Speaker: K. Pritchard-Jones
contrast agents
Chair: H. Wallace (United Kingdom)
(United Kingdom)
Speaker: K. Brindle (United Kingdom)
Improving success rates of sperm banking
SIOP neuroblastoma trials
Pitfalls in the interpretation of response
in adolescents
Speaker: R. Ladenstein (Austria)
in hodgkin’s lymphoma: the role of PEt
Speaker: To be announced
imaging
germ cell tumour trials
Speaker: C. Mauz Körholz (Germany)
advances in ovarian cryopreservation
Speaker: G.C. Calaminus (Germany)
Speaker: J. Donnez (Belgium)
Concluding remarks
SIOPEL liver trials
Speaker: A.C. Peet (United Kingdom)
advances in male fertility preservation
Speaker: P. Czauderna (Poland)
Speaker: A. Pacey (United Kingdom)
I-BfM Sg trials on childhood aLL
■
■ 13:30-14:30
discussion and roundup
Speaker: A. von Stackelberg (Germany)
debate: this house believes that teenage
Concluding remarks
and young adult units improve outcomes
■
■ 15:30-17:30
Speaker: J.R. Kowalczyk (Poland)
Moderator: K. Pritchard-Jones
Scientific Symposium: how to select
(United Kingdom)
a new drug in paediatric oncology
■
■ 14:45-16:45
Speaker in favour: L. Brugieres (France)
Chair: R. Riccardi (Italy)
Scientific Symposium: refining treatment
Seconder: A.W. Bleyer (USA)
Chair: G. Vassal (France)
and the cost of the cure - lessons from soft
Speaker against: D. Körholz (Germany)
tissue sarcoma in young people
Seconder: To be announced
Introduction
Speaker: R. Riccardi (Italy)
Chair: M.C.G. Stevens (United Kingdom)
■
■ 14:45-16:45
Chair: T.E. Klingebiel (Germany)
how to select a new drug in paediatric
Scientific Symposium: advances in
oncology (including early phase trials
Introduction
leukaemia
in solid tumours)
Speaker: M.C.G. Stevens (United Kingdom)
Speaker: G. Vassal (France)
Chair: A. Biondi (Italy)
Stratifying treatment for
Chair: M. Schrappe (Germany)
Phase I and II trial methodology
rhabdomyosarcoma
Speaker: B.J. Morland (United Kingdom)
Speaker: O. Oberlin (France)
Introduction
Speaker: A. Biondi (Italy)
Response assessment in new drug trials
Estimating the total burden of therapy
Speaker: A.C. Peet (United Kingdom)
Speaker: M.C.G. Stevens (United Kingdom)
Leukaemic stem cells and their
implications for therapy in childhood
Phase I/II studies in leukaemia
Synovial sarcoma: adult vs. paediatric
leukaemia
Speaker: A. Biondi (Italy)
approaches and the need for consensus
Speaker: E. Jacobsen (United Kingdom)
Speaker: A. Ferrari (Italy)
Ethical aspects of early phase clinical
genome wide approaches to identify new
trials in children
New approaches to the use of radiation
genetic alteration in childhood leukaemia
Speaker: F. Doz (France)
therapy in young people: efficacy vs.
Speaker: J.R. Downing (USA)
late effects
Concluding remarks
Speaker: M. Gaze (United Kingdom)
tailored treatment of childhood aLL
Speaker: G. Vassal (France)
Speaker: M. Schrappe (Germany)
Concluding remarks
Tuesday 22 September 2009
Speaker: T.E. Klingebiel (Germany)
Perspectives in cell and gene therapy of
childhood leukaemia
Speaker: A. Biondi (Italy)
■
■ 08:00-08:45
Wednesday 23 September 2009
Changing indications for stem cell
teaching Lecture: advances in fertility
■
■ 09:00-11:00
transplant in leukaemia in children and
preservation for children with cancer
young adults
Speaker: J. Donnez (Belgium)
Scientific Symposium: new imaging
Speaker: C. Peters (Austria)
approaches to response assessment in
childhood cancer
Concluding remarks
Speaker: M. Schrappe (Germany)
Chair: A.C. Peet (United Kingdom)
Chair: C. Mauz Korholz (Germany)
Introduction
Speaker: C. Mauz Korholz (Germany)

26
Patient advocacy / ethicS
Monday 21 September 2009
Overview of the burden of cancer in Europe
■
■ 16:30-17:30
Speaker: J.W. Coebergh (The Netherlands)
debate: this house believes that
■
■ 11:00-13:00
Economic burden of cancer on patients
individualised treatment will be the future
advocacy Session: advocacy in practice
Speaker: A. Leppanen (Sweden)
Moderator: H. Ludwig (Austria)
Chair: J. Fox (United Kingdom)
Psychological impact of cancer
Speaker in favour: C. Klein (Germany)
on the patient
Speaker against: R. Greil (Austria)
Opening Lecture: Patient groups - meeting
Speaker: J. Corner (United Kingdom)
the challenge of sustainable funding
Speaker: S. Kyriakides (Cyprus)
Return to working life with/after cancer
reGulatory / trial
Speaker: S. Rozman (Slovenia)
an overview of patient advocacy
methodoloGy / Pharmacy
Speaker: J. Fox (United Kingdom)
■
■ 11:00-12:00
Speaker: K. Oliver (United Kingdom)
Monday 21 September 2009
Speaker: H. Preuss (Germany)
advocacy Session: From patient to partner:
Speaker: H. Tavio (Finland)
evolution of the patient’s role in health care
■
■ 11:00-13:00
Speaker: E. Adarska (Bulgaria)
Chair: L. Faulds Wood (United Kingdom)
Scientific Symposium: methodology and
■
■ 13:45-15:15
from patient to partner: evolution of the
regulatory aspects of biotherapeutics and
patient’s role in health care
chemotherapeutics
advocacy Session: Informed cancer
Speaker: L. Denis (Belgium)
patients receive better treatment and care
Chair: C. Twelves (United Kingdom)
Speaker: L. Faulds Wood (United Kingdom)
Chair: J.-P. Bizzari (France)
Chair: A. Waldmann (Germany)
Speaker: J. Foubert (Belgium)
Introduction
Surviving childhood cancers
Why we need a patient voice in Europe
Speaker: C. Twelves (United Kingdom)
Speaker: A. Brownsdon (United Kingdom)
Speaker: A. Peterle (Slovenia)
RECISt 1.1
talking with patients about expensive
■
■ 13:00-14:30
Speaker: E.A. Eisenhauer (Canada)
(unavailable) new cancer drugs
Speaker: L. Fallowfield (United Kingdom)
advocacy Session: Cancer in the workplace
New imaging in cancer clinical trials
Speaker: B. Morgan (United Kingdom)
getting your share of good care -
Chair: I. Banks (United Kingdom)
an Eastern European perspective
a new paradigm for immunotherapy:
health literacy and active prevention -
Speaker: V. Cursaru (Romania)
novel endpoints
WhO campaign
Speaker: A. Hoos (USA)
Silent no more: cancer patients
Speaker: K. Rokho (Germany)
as advocates
“Clinical benefit”: myth or reality?
EU plan for a safer workplace
Speaker: D. Schmitt (Germany)
Speaker: C. Twelves (United Kingdom)
Speaker: F. Alvarez Hidalgo (Belgium)
Concluding remarks
■
■ 15:30-17:00
Early symptom recognition, disease
Speaker: J.-P. Bizzari (France)
management and work balance diagnosis
advocacy Session: access to clinical trials
and screening
Chair: J. Geissler (Germany)
Speaker: S. Boorman (United Kingdom)
Tuesday 22 September 2009
the patient perspective
Better use of services for migrant workers
■
■ 13:30-14:30
Speaker: R. Wilson (United Kingdom)
and cross border treatment
Speaker: M. Carballo (Switzerland)
Special Session: Individualisation of
trial publication and disclosure
treatment based on pharmacokinetics and
Speaker: R. Horton (United Kingdom)
■
■ 14:45-16:15
pharmacogenomics
Clinical trials registries and databases
advocacy Session: Improving cancer
Chair: P. Hartvig (Denmark)
Speaker: D. Ghersi (Switzerland)
outcomes through healthy lifestyle
Population-based PK/Pd modelling
access to trials: the investigator’s
choices
Speaker: S. Kästner (Sweden)
perspective
Chair: K. Redmond (Switzerland)
Speaker: A. Hochhaus (Germany)
genotyping and phenotyping
Benefits of exercise for cancer patients
Speaker: H.J. Guchelaar (The Netherlands)
■
■ 17:00-18:00
Speaker: F. Dimeo (Germany)
discussion and roundup
debate: do patient advocacy groups
CaM and cancer: the good, the bad and
represent the patients?
the ugly
Wednesday 23 September 2009
Speaker: E. Ernst (United Kingdom)
Chair: G. Feick (Germany)
Improving cancer outcomes by promoting
■
■ 13:30-14:30
Speaker in favour: E. Verschuur-van der
medicines adherence
Special Session: Special session on
Voort (The Netherlands)
Speaker: K. Redmond (Switzerland)
regulatory issues
Speaker against: T. Hudson (Italy)
Benefits of a healthy diet for cancer
Chair: D. Lacombe (Belgium)
patients
Tuesday 22 September 2009
Speaker: F. Berrino (Italy)
harmonisation of regulatory
requirements between the regions
■
■ 09:00-10:30
Speaker: F. Pignatti (United Kingdom)
advocacy Session: the burden of cancer
Chair: I. Kössler (Sweden)

ECCO 15 – ESMO 34
27
academic clinical trials: can they serve
■
■ 13:30-14:30
■
■ 14:45-16:45
a
regulatory purposes?
d
Special Session: dna repair of
Scientific Symposium: biological imaging
v
Speaker: To be announced
a
radiation damage
for adaptive radiotherapy
NCE
discussion and roundup
Chair: D. Zips (Germany)
Chair: V. Gregoire (Belgium)
P
RO
Chair: V. Khoo (United Kingdom)
■
■ 17:00-18:00
What is new in dNa repair of
g
R
radiation damage?
Introduction
a
debate: this house believes that genomic
MME
Speaker: G. Iliakis (Germany)
Speaker: V. Gregoire (Belgium)
signatures will be useful for personalised
medicine
how can we utilise dNa repair assays
Biological imaging in treatment planning
in prediction of radiation response?
Speaker: M. Alber (Germany)
Moderator: J. Soria (France)
Speaker: A. Kiltie (United Kingdom)
Speaker in favour: R. Bernards
Clinical status of bio-imaging
(The Netherlands)
discussion and roundup
for radiotherapy
Seconder: F. Cardoso (Belgium)
Speaker: V. Valentini (Italy)
Speaker against: K.K. Jain (Switzerland)
■
■ 15:30-17:30
functional imaging methods for oncology
Seconder: E. Domany (Israel)
Scientific Symposium: GenepI: genetic
Speaker: N. Sibson (United Kingdom)
prediction of radiation damage - where do
Thursday 24 September 2009
validation of bio-imaging methods
we stand?
for radiotherapy
Chair: A.C. Begg (The Netherlands)
Speaker: D. Zips (Germany)
■
■ 09:00-11:00
Chair: J. Overgaard (Denmark)
Concluding remarks
Scientific Symposium: monitoring and
Introduction
Speaker: V. Khoo (United Kingdom)
management of adverse drug events
Speaker: A.C. Begg (The Netherlands)
Chair: A. Astier (France)
European tissue and database
Wednesday 23 September 2009
Chair: K. Meier (Germany)
infrastructure
Introduction
Speaker: K. Haustermans (Belgium)
■
■ 08:00-08:45
Speaker: A. Astier (France)
Low dose cell responses - predictors of
teaching Lecture: Imrt and biological
Management of adverse drug events
normal tissue damage after radiotherapy?
approaches in radiotherapy for
Speaker: U. Jaehde (Germany)
Speaker: P. O’Neill (United Kingdom)
prostate cancer
Speaker: R. Bristow (Canada)
Identification and prevention of
genetic markers of normal tissue effects
drug-drug interactions
after radiotherapy
■
■ 13:30-14:30
Speaker: A. Liekweg (Germany)
Speaker: E. Dikomey (Germany)
Special Session: Cancer stem cells and
adverse drug events of targeted therapies
gene level and epigenetic predictors
radiation resistance
Speaker: To be announced
Speaker: J. Alsner (Denmark)
Chair: R. Bristow (Canada)
Prevention therapy of fatigue
Concluding remarks
Speaker: P. Hartvig (Denmark)
Speaker: J. Overgaard (Denmark)
Radioresistance of cancer stem cells
Speaker: F. Pajonk (USA)
Concluding remarks
Speaker: K. Meier (Germany)
Tuesday 22 September 2009
Cancer stem cells as determinant of
tumour radioresistance
■
■ 11:15-12:15
■
■ 08:00-08:45
Speaker: M. Baumann (Germany)
Special Session: trial methodology
teaching Lecture: the value of new
discussion and roundup
imaging technology for target volume
Chair: P. Paoletti (USA)
delineation
■
■ 14:45-16:45
the role of randomised trials and
Speaker: V. Khoo (United Kingdom)
Scientific Symposium: targeting in
surrogate biomarkers in early clinical
radiotherapy
development
■
■ 13:30-14:30
Speaker: M. Buyse (Belgium)
Chair: To be announced
Special Session: Very late normal tissue
Chair: J. Bourhis (France)
Integration of diagnostic markers into the
damage after radiotherapy
development process of targeted agents
Introduction
Chair: S.M. Bentzen (USA)
Speaker: R. Simon (USA)
Speaker: To be announced
dose distribution and risk
discussion and roundup
targeting the tumour stroma
Speaker: K.R. Trott (United Kingdom)
Speaker: N. Cordes (Germany)
Long term risks after radiotherapy
radiotheraPy / radioBioloGy
how to address interlinkage of pathways
of testicular cancer
Speaker: H.P. Rodemann (Germany)
Speaker: S.D. Fossa (Norway)
Monday 21 September 2009
discussion and roundup
■
■ 08:00-08:45
teaching Lecture: hadron therapy
Speaker: J. Debus (Germany)

28
Improving radiotherapy by targeting the
■
■ 14:45-16:45
Comprehensive management of
bone marrow derived stroma
gastrointestinal cancer: focus on
Scientific Symposium: Special therapies
Speaker: M. Brown (USA)
appendiceal mucinous neoplasms
for special sarcoma subtypes
and gastric cancer
the experience from EPO
Chair: P. Schöffski (Belgium)
Speaker: P.H. Sugarbaker (USA)
Speaker: J. Overgaard (Denmark)
Introduction
discussion and roundup
Concluding remarks
Speaker: P. Schöffski (Belgium)
Chair: J. Bourhis (France)
■
■ 15:30-17:30
taxanes in angiosarcomas
■
■ 17:00-18:00
Speaker: M. Schlemmer (Germany)
Scientific Symposium: Quality assurance
and audit in colorectal cancer in europe
debate: this house believes that
aromatase-inhibitors
hypofractionation should be standard of
in gynaecological sarcomas
Chair: C.J.H. van de Velde (The Netherlands)
care in breast cancer
Speaker: A. Poveda Velasco (Spain)
Chair: L. Påhlman (Sweden)
Moderator: H. Bartelink (The Netherlands)
gemcitabine-based therapy for
Introduction
Speaker in favour: J. Yarnold (United Kingdom)
leiomyosarcomas? for all?
Speaker: C.J.H. van de Velde (The Netherlands)
Seconder: W. Budach (Germany)
Speaker: I. Ray-Coquard (France)
the Norwegian programme
Speaker against: J. Overgaard (Denmark)
tyrosine-kinase inhibitors in very rare
Speaker: A. Wibe (Norway)
Seconder: J. Jassem (Poland)
sarcoma subtypes
the Swedish programme
Speaker: J.-Y. Blay (France)
Thursday 24 September 2009
Speaker: L. Påhlman (Sweden)
Concluding remarks
the UK programme
Speaker: P. Schöffski (Belgium)
■
■ 08:00-08:45
Speaker: J. Smith (United Kingdom)
teaching Lecture: personalised
Thursday 24 September 2009
an ECCO initiative for Europe
radiotherapy - what is evidence-based?
Speaker: C.J.H. van de Velde (The
Speaker: C. Belka (Germany)
Netherlands)
■
■ 08:00-08:45
Concluding remarks
■
■ 11:15-12:15
teaching Lecture: how to choose your
Speaker: L. Påhlman (Sweden)
treatment options for desmoids
Special Session: new approaches for
Speaker: A. Gronchi (Italy)
evidence generation of novel radiation
Tuesday 22 September 2009
technologies
■
■ 11:15-12:15
Chair: D.R. Olsen (Norway)
■
■ 08:00-08:45
Special Session: Sarcomas in adolescents
assessing clinical benefit from new
teaching Lecture: mission accomplished
Chair: To be announced
radiation oncology technologies
or work in progress - laparascopic vs open
Speaker: S.M. Bentzen (USA)
Managing sarcomas in teenagers
colorectal surgery
and young adults
Speaker: W. Schwenk (Germany)
development and assessment of novel
Speaker: J. Whelan (United Kingdom)
radiation technique - a medical physics
■
■ 13:30-14:30
perspective
Biological mechanisms underlying
Speaker: D. Jaffray (Canada)
differences in outcomes between children
Special Session: the management
and adolescents
of GISt tumours
discussion and roundup
Speaker: To be announced
Chair: P. Naredi (Sweden)
discussion and roundup
Sarcoma: Soft tiSSue
Surgery perspective
and Bone
Speaker: P. Hohenberger (Germany)
SurGical oncoloGy
Medical oncology perspective
Wednesday 23 September 2009
Speaker: S. Sleijfer (The Netherlands)
Monday 21 September 2009
discussion and roundup
■
■ 13:30-14:30
■
■ 08:00-08:45
Special Session: Sarcoma orientated
Wednesday 23 September 2009
teaching Lecture: Image-guided surgery
networks of exellence in europe II
Speaker: C.W.G.M. Lowik (The Netherlands)
■
■ 08:00-08:45
Chair: J.-Y. Blay (France)
■
■ 13:30-14:30
teaching Lecture: an update of sentinel
EuroBoNet
node biopsy on breast cancer
Speaker: P.C.W. Hogendoorn
Special Session: management of
Speaker: R.E. Mansel (United Kingdom)
(The Netherlands)
peritoneal disease
ConticaBase, the virtual bank of
Chair: I. Taylor (United Kingdom)
■
■ 13:30-14:30
Conticanet
Present and future of hIPEC in colorectal
Special Session: Sentinel node staging and
Speaker: J.-M. Coindre (France)
carcinomatosis
clinical implications in GI tract
discussion and roundup
Speaker: D. Elias (France)
Chair: T. Lehnert (Germany)

ECCO 15 – ESMO 34
29
any value in colorectal cancer?
Thursday 24 September 2009
Minichromosome maintenance proteins
a
Speaker: R.A.E.M. Tollenaar
as markers for cancer screening
d
v
(The Netherlands)
■
■ 09:00-11:00
Speaker: N. Coleman (United Kingdom)
a
NCE
Oesophagus/stomach cancer
Scientific Symposium: Communication
■
■ 17:00-18:00
P
Speaker: P.M. Schlag (Germany)
crisis in oncology
RO
educational Symposium: all you wanted
g
discussion and roundup
Chair: M. Aapro (Switzerland)
R
to know about cancer stem cells but were
a
Chair: N.I. Cherny (Israel)
MME
afraid to ask
Thursday 24 September 2009
Introduction
Chair: M. Alison (United Kingdom)
Speaker: M. Aapro (Switzerland)
■
■ 08:00-08:45
Stem cells and digestive organ cancer
Managing the family which demands that
Speaker: M. Alison (United Kingdom)
teaching Lecture: t1/t2 rectal
the patient not to be told
cancer treatment
Speaker: N.I. Cherny (Israel)
Breast cancer stem cells
Speaker: N.J. Mortensen (United Kingdom)
Speaker: B. Groner (Germany)
discussing a treatment error with the
patient and his/her family
Cancer stem cells in haematological
■
■ 11:15-12:15
Speaker: A. Surbone (Italy)
malignancies - implications for
Special Session: Lymphadenectomy for
understanding pathogenesis and
When the patient doesn’t want the
GI cancer - does it make a difference?
targeted therapy
treatment that you think they need
Speaker: H.E. Johnsen (Denmark)
Chair: C.J.H. van de Velde (The Netherlands)
Speaker: To be announced
Oesophagus cancer
Raising end of life issues when the patient
Wednesday 23 September 2009
Speaker: T. Lerut (Belgium)
is still focused on treatment
Speaker: L. Deliens (Belgium)
gastric cancer
■
■ 13:30-14:30
Speaker: S.A. Hundahl (USA)
Concluding remarks
Special Session: Imaging in drug
Speaker: N.I. Cherny (Israel)
Colorectal cancer
development
Speaker: P.M. Schlag (Germany)
Chair: E. Aboagye (United Kingdom)
discussion and roundup
tranSlational reSearch
Imaging in early drug development -
Monday 21 September 2009
the pharmacology audit trail
SymPtom Science
Speaker: S. Galbraith (USA)
■
■ 15:30-17:30
Imaging in Phase I-III trials
Wednesday 23 September 2009
Speaker: To be announced
Scientific Symposium: resistance
mechanisms to eGFr and her2 inhibitors
discussion and roundup
■
■ 08:00-08:45
and strategies to overcome them
teaching Lecture: antiemetics: state-
■
■ 14:45-16:45
Chair: F. Cappuzzo (Italy)
of-the-art
Chair: Y. Yarden (Israel)
Scientific Symposium: targeting tumour
Speaker: J. Herrstedt (Denmark)
cell signalling
Introduction
■
■ 14:45-16:45
Speaker: F. Cappuzzo (Italy)
Chair: To be announced
Chair: R. Marais (United Kingdom)
Scientific Symposium: Symptom
an overview of resistance to anti-EgfR/
management: from molecular biology to
hER2 agents
Introduction
bedside including pain and cachexia
Speaker: J. Baselga (Spain)
Speaker: To be announced
Chair: S. Kaasa (Norway)
PI3 kinase
the Raf-kinase family and cancer
Chair: M. Fallon (United Kingdom)
Speaker: K. Berns (The Netherlands)
Speaker: R. Marais (United Kingdom)
Introduction
Igf-I receptor
therapeutic strategies for targeting BRaf
Speaker: M. Fallon (United Kingdom)
Speaker: F.J. Esteva (USA)
in human cancer
Speaker: D. Solit (USA)
genotyping - does it matter in clinical
RaS
practice for pain and cachexia
Speaker: A. Bardelli (Italy)
the MEt oncogene: physiology and
Speaker: K.C. Fearon (United Kingdom)
pathology of invasive growth
Concluding remarks
Speaker: P.M. Comoglio (Italy)
assessment and classification
Speaker: Y. Yarden (Israel)
of pain and cachexia
MEt inhibitors in cancer therapy
Speaker: S. Kaasa (Norway)
Tuesday 22 September 2009
Speaker: To be announced
Cancer pain treatment. New approaches
Concluding remarks
based upon the WhO pain ladder
■
■ 08:00-08:45
Speaker: R. Marais (United Kingdom)
Speaker: M. Fallon (United Kingdom)
teaching Lecture: dna replication
■
■ 17:00-18:00
treatment of cachexia-a preventive or
proteins as biomarkers in cancer
symptomatic approach?
Special Session: Circulating tumour cells
dNa replication proteins as
Speaker: F. Strasser (Switzerland)
biomarkers in cancer
Chair: J. de Bono (United Kingdom)
Concluding remarks
Speaker: R. Laskey (United Kingdom)
Speaker: S. Kaasa (Norway)

30
Methods for detection of circulating
■
■ 13:30-14:30
Thursday 24 September 2009
tumour cells: potential & limitations
Special Session: oncology societies: why?
Speaker: C. Panabieres (France)
■
■ 08:00-08:45
Chair: M. Ballieu (Belgium)
Characterisation and monitoring
teaching Lecture: evidence-
of circulating tumour cells
Introduction
based medicine: development and
Speaker: K. Pantel (Germany)
Speaker: M. Ballieu (Belgium)
implementation of guidelines in oncology
Speaker: N. Pavlidis (Greece)
the prognostic and therapeutic
ESSO
implications of circulating tumour
Speaker: To be announced
■
■ 09:00-11:00
cells in breast cancer
EStRO
Speaker: O. Fodstad (Norway)
Scientific Symposium: multidisciplinary
Speaker: L.P. Muren (Denmark)
teams in cancer care
discussion and roundup
ESMO
Chair: To be announced
Speaker: E. Martinelli (Italy)
Chair: E. De Azambuja ( Belgium)
younG oncoloGiStS
EaCR
Multidisciplinary teams: what are they,
Speaker: R.J. White (United Kingdom)
Wednesday 23 September 2009
how do they work?
discussion and roundup
Speaker: H.J. Schmoll (Germany)
■
■ 08:00-08:45
the impact of Mdt meetings on cancer
■
■ 14:45-16:45
patient management
teaching Lecture: the challenge of
Scientific Symposium: Innovations in early
Speaker: A.-J. Ramirez (United Kingdom)
interacting with patients
clinical trials
Speaker: L. Fallowfield (United Kingdom)
Moderator
Chair: S. Di Cosimo (Spain)
Speaker: To be announced
■
■ 09:00-11:00
Chair: C. Twelves (United Kingdom)
Case presentation 1: Lung - Radiotherapist
Scientific Symposium: FLImS Symposium
Introduction
Speaker: To be announced
and eCCo/eJC award
Speaker: S. Di Cosimo (Spain)
Case presentation 2: Breast -
Chair: To be announced
Phase O clinical trials: facts and promise
Medical Oncologist
Chair: O. Belvedere (United Kingdom)
Speaker: To be announced
Speaker: C. Palmieri (United Kingdom)
the flims Workshop
Use of biologics in drug development
Case presentation 3: Rectal - Surgeon
Speaker: To be announced
Speaker: T. Morgillo (Italy)
Speaker: To be announced
flims alumni Club (faC)
Phase I setting up and running: the fellow
discussion and roundup
Speaker: M. Erman (Turkey)
point of view
Speaker: To be announced
■
■ 11:15-12:15
Presentation of a flims study
Speaker: O. Belvedere (United Kingdom)
Novel tool for drug efficacy testing
Special Session: Career development
Speaker: M. Ignatidis (Belgium)
opportunities after your degree
Presentation of a flims study
Speaker: To be announced
Concluding remarks
Chair: F. Ciardiello (Italy)
Speaker: C. Twelves (United Kingdom)
Q & a / discussion
Clinical fellowship opportunities in
Europe
Introduction of the ECCO/EJC Young
Speaker: M. Piccart (Belgium)
Investigator award winner
Speaker: To be announced
Clinical fellowship opportunities in the U.S.
Speaker: J. King (USA)
ECCO/EJC Young Investigators award
Award Lecturer: To be announced
discussion and roundup

ECCO 15 – ESMO 34
31
Notes
a
d
v
a
NCE
P
RO
g
R
a
MME

32
Call for abstracts

D Certifies that the information in the abstract is for
Abstracts can only be submitted online at:
exclusive presentation in the ECCO 15 – ESMO 34 scientific
www.ecco-org.eu
programme and will not be presented as such during the
abstract submitted by regular mail, fax or E-mail
conference at any industry-related Satellite Symposia.
will NOt be accepted

D States that for all studies involving human or animal
subjects, permission has been obtained from the
Abstract submission deadline: 29 April 2009, 09.00 p.m.
relevant regulatory authority and properly informed
(21:00 hrs) Central European Time
consent given where appropriate.
It is strongly advised that presenting authors should

D abstracts that include clinical trial data include the
submit their abstract before the day of the deadline,
following information in the body of the abstract: trial
otherwise authors may experience technical delay due
abbreviation, trial Registry Number or Id background,
to server overload.
Objective, design, Population studied (including sample
size), Intervention, Outcome measure(s), analysis, trial
status, trial sponsor(s).
to consult the ECCO 15 – ESMO 34 abstract submission
programme visit: www.ecco-org.eu.

D Identifies any financial interest in products or processes
described in the abstract. the presenting author is
requested to tick the “Conflict of interest” box when
the ECCO 15 – ESMO 34 Scientific Committee strongly
submitting the abstract and to provide disclosure
encourages the submission of abstracts on Phase I,
of interests and relationships through the abstract
Phase II and large phase III trials coming to an end or
submission programme. this includes stock ownership,
having new data available mid 2009. Please refer to
membership on an advisory board or board of directors,
‘Late-Breaking abstracts Policy & Regulations’ on page 34.
corporate-sponsored research, or other substantive
relationships.
Abstracts on case studies will be rejected.

D Releases the copyright to ECCO and gives permission
Abstract Policies & Regulations
for the abstract, when selected for presentation, to be
published in the ECCO 15 – ESMO 34 abstract Book with
With the submission of an abstract to ECCO 15 –
the European Journal of Cancer (EJC) Supplement
ESMO 34 Congress, the first (presenting) author:
(in printed and electronic format), as well as on the

D Certifies to be an investigator with a substantial
ECCO 15 – ESMO 34 website.
involvement in the clinical study presented in
the abstract.
Abstract Preparation & Submission

D accepts responsibility for the accuracy of the submitted
Abstract Format
abstract - please proof read the abstract carefully prior

D the title of the abstract should be brief and objectively
to submission.
describe the study. do not use capital letters in the title

D accepts the rule that a first (presenting) author can be
except for words that are always capitalized and do not
the first (presenting) author of only one abstract.
use non-standard abbreviations. Commercial names may
not be used in the abstract’s title (generic names only).

D accepts to be the contact person for all correspondence
about the abstract and inform co-authors about its status.

D No more than 10 authors can be listed with
institutional affiliations, cities and countries only.

D Confirms that all co-authors are aware of and agree to the
Mailing addresses and academic degrees should not be
content of the abstract and support the data presented.
mentioned in the author’s list. for cooperative study

D Warrants that the data and conclusions presented in the
groups, you may give the name of the group instead of
abstract have not been presented or published at any
individual institutional affiliations or include the name
meeting of 500 delegates or more prior to ECCO 15 –
of the group in the title of the abstract.
ESMO 34 Congress. for important large studies,

D abstracts should be structured in such a way as to
presented (in part) at previous meetings, authors are
include the following 4 sections:
encouraged to provide updated data. violation of
this policy may result in a rejection of the submitted
abstract.

ECCO 15 – ESMO 34
33
C
a
LL
f
OR
(1) Background: an introductory sentence indicating the

D Submitting an abstract for presentation at
a
BS

purpose of the study
ECCO15 – ESMO 34 does not constitute registration for
t
R
(2) Material and methods: a brief description of
the conference. abstract presenters must register to
a
C

pertinent experimental procedures
attend ECCO 15 – ESMO 34 by following the instructions
t
S
(3) Results: a summary of the results of the research
for registration on the website
(4) Conclusions: a statement of the main conclusions

D the on-line abstract submission procedure will not
PrESENTATION PrEFErENCE
accept abstracts that exceed 2500 characters (body of
Oral, poster or no preference: the final decision on
the abstract, including spaces and table).
the presentation format will be made by the Scientific
Committee.

D Only one data table is permitted in the body of the
abstract. Illustration and figures are not allowed and
TOPIC CATEgOrY
will be deleted if submitted.
Choose ONE topic category ONLY that refers to the main

D Abbreviations may be used if standard or if spelled
subject of the abstract.
out and defined at the first use (put in parentheses
immediately after the first mention of a term or phrase).
KEYWOrDS
Compounds should be mentioned with the generic
authors have to provide 3 keywords (different from
name, in lower cases. Commercial names are admitted
category). the Scientific Committee has the authority
in the text, with an®, and if in brackets following the
to re-categorise and re-key the abstract.
generic name, i.e. “generic (Commercial®)”.
for questions regarding the on-line submission process,
contact Pat vanhove by Email: pat.vanhove@ecco-org.eu,

D the abstract must be submitted in good English. the
or tel: +32 2 775 02 42.
Scientific Committee reserves the right to reject those
abstracts which are presented in poor English, or may
Abstract Selection Process
request an immediate revision by the presenter.
abstracts submitted for presentation at ECCO 15 – ESMO 34
Abstract Submission Procedure
will be reviewed by an international panel of experts
in the field of the subject and will be judged solely on
abstracts can ONLY be submitted on-line via the ECCO
the data submitted.
website www.ecco-org.eu.
the following presentation formats are applicable

D When finished with the online submission, click the
at ECCO 15 – ESMO 34:
“fINaL SUBMISSION” button for the final submission
OrAl PrESENTATION: the abstract is selected for oral
of your abstract. as a confirmation of your submission,
presentation at any of the proffered papers sessions.
a message will appear on the screen informing you the
abstracts of superior quality can be selected for presentation
abstract has been succesfully submitted to our database.
in a session where discussants will place the research

D If you need to edit your abstract at a later stage please
findings into perspective.
click ‘SavE aNd CLOSE’. this button allows you to update
your abstract before final submission.
POSTEr SESSION: abstracts that have been selected for
presentation in poster format will be displayed on poster
PlEASE NOTE: after clicking ‘SAVE AND ClOSE’, your
boards. the posters are grouped by topic and are displayed
abstract is NOT submitted. You need to return to the
for three hours. a specific time is devoted to poster viewing.
abstract submission page, finalise your abstract and
click ‘FINAl SUBMISSION’.
POSTEr DISCUSSION SESSION: experts in the field are

D Within 48 hours of submission, the presenting author
chosen to provide a themed overview and discussions
will receive an e-mail to confirm that ECCO has received
of the findings from selected abstracts. first authors of
the abstract. this confirmation of abstract does not
abstracts that have been selected for poster discussion
mean your abstract has been selected for presentation.
session will be invited to submit the poster electronically
in advance of ECCO 15 – ESMO 34 (details will follow

D In case the confirmation from the ECCO 15 – ESMO 34
in due course).
Secretariat is not received, please contact the secretariat
(pat.vanhove@ecco-org.eu) within one week after the
WIThDrAWAl OF ABSTrACTS: abstracts submitted for
submission of the abstract.
presentation at ECCO 15 – ESMO 34 can be withdrawn until

34
15 May 2009. after this date, abstracts selected for oral or
abstract does not meet the criteria for oral presentation
poster presentations should be presented. If the presenting
in one of these two sessions, the abstract may be
author of a selected abstract cannot attend, he/she should
considered for poster presentation or be rejected.
assign a replacement and inform ECCO of the replacement

D Late-breaking abstracts will undergo formal peer-
as soon as possible.
review evaluation by the Scientific Committee.
the presenting author will receive a letter with the result
Submission
of the review and the Scientific Committee’s decision on
a call for late-breaking abstracts will be made in June.
the abstract by the end of June/early July 2009.
Online submission will be open from 22 July until
Late-Breaking Abstracts –
5 August 2009.
Policy & Regulations
Place holder abstracts NOt required.
Definition
the first (presenting) author must:

D Late-breaking abstracts should highlight novel and

D Submit an abstract by the submission deadline
practice changing studies. The late-breaking abstract
of 5 august 2009.
deadline is not intended to be merely an extension
of the general submission deadline. It will focus on

D Complete the section on the reasons why this abstract
capturing abstracts with ground-breaking and unique
should be considered as late-breaking (In order for the
data that would not otherwise have been presented at
abstract to be considered late breaking, this section
the conference.
must be completed).

D Examples of suitable late-breaking abstracts might

D Ensure that submission of the abstract follows the
include the results of a practice-changing prospective
general abstract submission guidelines and regulations
Phase III clinical trial, a Phase II study showing anti-
and the specific guidelines listed above.
tumour activity in a novel context, an early clinical trial

D Ensure abstracts that include clinical trial data
with novel proof-of-principle data, the demonstration
include the following information in the body of the
of novel cancer biology with therapeutic implications;
abstract:trial abbreviation, trial Registry Number or
in each case the results should not have been fully
Id background, Objective, design, Population studied
available by the general abstract submission deadline.
(including sample size), Intervention, Outcome

D the data in the abstract must not be published
measure(s), analysis, trial status, trial sponsor(s).
(manuscript or abstract) prior to the conference.

D Ensure that abstracts contain final results and

D The late breaking abstract deadline is 5 August 2009.
incorporate statistical analysis.

D abstracts submitted stating “results to follow” or similar
Policy
deferment will not be considered.
abstracts from translational, Phase I, Phase II or Phase III
SElECTION
studies for which preliminary data were not available at

D the final decision for late-breaking abstracts will be
the time of the abstract submission deadline of 29 april
taken by 10 august 2009. abstracts will be judged solely
2009 will be considered for presentation at the ECCO 15 –
on the data submitted. the first (presenting) author will
ESMO 34 Congress.
receive confirmation of acceptance or rejection before
20 august 2009.

D data from the long-term follow-up of previously
presented clinical trials may be submitted only if
Embargo Policy
significant new information can be shown. In this case,
please ask for special consideration by email. these

D abstracts submitted to ECCO15 – EMSO 34 are
abstracts will usually be considered for poster/ poster
considered to be embargoed until the first day of the
discussion presentations only.
scientific programme

D Interim analysis of a prospective randomized clinical

D Information contained in the abstract as well as
trial will be considered only if it is performed as planned
additional data and information to be presented
in the original protocol and is statistically valid. If your
must not be made public before the abstract has been
abstract involves interim analysis, explain the details of
published or presented at ECCO15 – ESMO 34.
your study in the body of the abstract.

D the first author and co-authors must not release the

D Late-breaking abstracts will be considered for oral
research/study to news media.
presentation either in proffered papers sessions or in

D If the policy is violated, the abstract will be automatically
one of the 3 Presidential sessions. If a late-breaking
withdrawn from presentation and from publication online.

ECCO 15 – ESMO 34
35
Topic Categories
C
a
LL
Please select ONE topic which refers to the main subject of the abstract.
f
OR
a
BS
Basic Science
Sarcoma
t
R
a
C
Translational Research
Symptom Science
t
S
Drug Development
Including complications, palliative care, psychosocial
aspects, quality of life management

– Preclinical

– Phase I
Other - only if none of the provided topics apply
Breast Cancer
Oncology Nursing

– Breast cancer - Clinical early disease
Please select one topic:

– Breast cancer - Clinical advanced disease

– advanced nursing roles

– Impact of cancer on patients and families
Cancer in the Elderly

– assessment and measurement in cancer care
Central Nervous System

– Survivorship

– Symptoms and symptom clusters
Diagnostic/Biomarkers

– Supportive and palliative care
Epidemiology and Prevention

– Clinical research and cancer outcomes

– Managing cancer services
Gastro-intestinal Malignancies – Colorectal Cancer

– Quality of cancer care
Gastro-intestinal Malignancies – Non-Colorectal Cancer
Genitourinary Malignancies – Prostate Cancer
Genitourinary Malignancies – Other
Gynaecological Cancers
Head and Neck Cancer
Imaging
Including radiology, nuclear medicine, interventional,
functional and molecular imaging
Haematological Malignancies and Myeloma
Lung Cancer - NSC, SC and pleural
Melanoma and Skin Cancer
Paediatric Oncology
Public Health, Health Economics, Policy
Radiotherapy and Radiobiology
Including radiobiology and non disease specific
radiotherapy techniques only

36
Registration
Individual Registration
Pre-registration and corresponding payments should be received before the indicated deadlines.
Please register online via www.ecco-org.eu. If you do not have internet access, please complete the registration form
enclosed in this brochure and return it by fax or post.
Individual Registration Fees
Register early to attend ECCO 15 – ESMO 34 and benefit from significant savings on fees:
Registration fees
Early Rate closes
Regular Rate closes
desk Rate as of
31/03/2009
03/08/2009
04/08/2009
Members (*)

385 €

825 €

925 €
Non Members

565 €

895 €

925 €
developing Economies (**)

100 €

n/a

n/a
Students/ Junior Participant ‘in training’ (***)

150 €

150 €

150 €
Patient advocates

200 €

200 €

200 €
Spouse ticket (****)

90 €

90 €

90 €
all registration fees include local vat (19%).
(*)
discounted membership rates apply for individuals who
(***) Confirmation of ‘in training’ status and a letter from the
are a member of the following professional associations:
head of department is required. these documents should
EaCR, EONS, ESMO, ESSO, EStRO, SIOP Europe, EaNO, EaU,
be sent to the ECCO 15 - ESMO 34 Congress Secretariat by
EORtC, ESgO, ESO, ESOP, EUSOMa, BIg, EaNM, EBMt, ECL,
fax: +32 2 775 02 00
Europa donna, Europa Uomo, Euroskin, faC, Myeloma

Euronet, OECI, UICC.
(****) this ticket includes access to the Welcome Reception on

Sunday, 20 September 2009, as well as a guided Sightseeing
(**)
Countries with a Purchasing Power Parity (PPP) per capita
tour of Berlin on Monday, 21 September 2009. N.B.: No
of less than US$ 10.000 per annum according to the World
access to scientific sessions or the exhibition is granted.
Bank listing available at: www.worldbank.org

Payment
full payment in EUR should be received before the corresponding deadline, otherwise the preferential
rate will not be granted.

Payment by credit card (Eurocard/Mastercard, visa or american Express) is preferred. Please indicate the owner’s name
as shown on the card.

It is also possible to pay by direct transfer to the ECCO 15 – ESMO 34 bank account:
IBaN BE21 7330 3489 7903
Swift/BIC Code: KREdBEBB
KBC Bank, Chaussée de Wavre 1662, B-1160 Brussels

to facilitate easy processing, please be sure to indicate clearly the name of the participant(s), and add the reference
“Registration fee ECCO 15 – ESMO 34” on the transfer document.

Registrations on-site can only be paid by credit card (Eurocard/Mastercard, visa or american Express) or in cash (Euros only).

ECCO 15 – ESMO 34
37
RE
g
IS
Confirmation of Registration
t
R
a
t
a personalised confirmation Email will be sent to each participant once payment of the registration fee has been received in
ION
the Congress’s bank account.

approximately two weeks before the start of the Congress each confirmed participant will receive an additional e-mail
including their personalised identification barcode (for easy and fast access to the Congress) as well as important logistical
information about the Congress.

Replacements / Cancellations
Replacements of confirmed registrations are subject to an administrative fee of 75 € per participant. Cancellation of
confirmed registrations are subject to a charge of 100 € cancellation fee per participant provided the cancellation is received
by 03 August 2009. Refunds by credit card or bank transfer will be made after the Congress.

For cancellations received after 03 August 2009 no refunds will be made.

Group Registration
Companies and agencies that would like to sponsor the registration fees of a group of participants may do so using the special
group registration form that is available on the ECCO 15 – ESMO 34 website www.ecco-org.eu.
Important Notice: Please do not register group participants individually online – if you do so, your participants
will not be considered as part of a group. Please also note that smaller groups of less than 10 persons will be handled as
individual registrations.
Group Registration Fees
delegate
developing
Spouse
Economies (*)
ticket (**)
Early Rate closes 31/03/2009

565 €

100 €

90 €
Regular Rate closes 03/08/2009

895 €

n/a

90 €
desk Rate as of 04/08/2009

925 €

n/a

90 €
Should you require any additional information or have specific queries please contact Riitta Kettunen via Email at:
riitta.kettunen@ecco-org.eu, or by fax: +32 2 775 0200.

Accompanying Person Registration (Spouse Ticket)
Each participant who subscribes for full registration at ECCO 15 – ESMO 34 can register a maximum of one accompanying
person (spouse ticket). the rate applied is 90 € and allows access to the Welcome Event and Berlin City tour on Monday
21 September 2009.

SA-CP-WithCode_SK11A02_P01139 19/12/08 16:23 Page 1
SAVE UP TO 20%
ON GETTING TO YOUR
CONVENTION WITH
CONVENTIONS PLUS
It’s easy to save money on your flights if you fly the Star Alliance™
network. Simply quote the event code SK11A02 when you make your
booking with any Star Alliance member airline and you’ll automatically
get a discount of up to 20%.
The Star Alliance network has 24 member airlines with over 18,100
flights a day so we can offer you a lot more choice when planning your
travel. For more information about our member airlines and contact details,
please visit our website at www.staralliance.com/conventionsplus
www.staralliance.com
Information correct as at 07/2008

ECCO 15 – ESMO 34
39
fellowship grants &
f
ELL
Educational awards
O
WS
h
Fellowship Grants
The ECCO 15 – ESMO 34 Organising Committee will
IP
g
select the recipients of the Fellowship grants and
R
through the generosity of the ECCO 15 – ESMO 34 Sponsors,
a
Educational Awards. Successful applicants will be
N
a number of fellowship grants are offered to young
t
notified throughout the course of July 2009.
S

&
researchers (doctors, basic scientists and nurses) from

E
d
countries with limited resources to attend the Congress.
UC
ECCO – the European CanCer organisation / the European
a
Journal of Cancer (EJC) Young Investigator's Award
t
ION
to meet the requirements to be considered for a fellowship
grant the applicant should:
a
L
ECCO – the European CanCer Organisation and Elsevier,
a
W
publisher of EJC are pleased to announce the ECCO /EJC Young
a

D Submit an abstract for ECCO 15 – ESMO 34. applicants
R
Investigator’s award, to be presented at ECCO 15 – ESMO 34.
d
S
whose abstracts have been accepted for an oral or poster
presentation at ECCO 15 – ESMO 34 will be considered first.
the ECCO/EJC Young Investigator’s award is open to young
basic scientists and clinical oncologists of all disciplines

D Be under the age of 40 and have a primary focus in
relevant to cancer research. the award will be given to a
clinical or experimental oncology or cancer nursing.
young scientist or doctor in the field of basic, translational

D Provide a letter of support from the head of the
or clinical oncology research for recent original work in
department/Organisation stating that the applicant
cancer research, treatment or care.
is not the recipient of any other financial support,
including a copy of the submitted abstract.
the following criteria for application will apply:
– candidates should be junior (within 5 years of

D Provide a two page Cv (including date of birth).
completion of Phd or specialist training)
– candidates should have completed the submitted work
The deadline for receipt of applications is 29 April 2009
in the period between april 2007 and april 2009
(abstract submission deadline). Incomplete applications
– submissions should be sent in by the candidate together
will not be considered.
with a reference letter from their head of department
– the work may be the result of individual research or
Each fellowship grant shall be worth a free registration,
the result of a thesis completed in the field of basic,
free accommodation for a maximum of 4 nights and
translational or clinical research
reimbursement of travel costs up to a maximum of 500 EUR
– candidates should commit themselves to write an
(reimbursement after the conference).
original paper in English on the scientific work carried
out (for publication in EJC)
Please complete the online application form on
www.ecco-org.eu
thE aPPLICatION ShOULd INCLUdE
Educational Awards
thE fOLLOWINg dOCUMENtS:
– a summary of the research work (maximum 2 pages) and
an additional number of educational awards will be
copies of recently published or submitted manuscripts
provided to clinicians and nurses who are not involved in
of the applicants work, to be submitted in English
research, to attend ECCO 15 – ESMO 34.
– a curriculum vitae and a list of publications
– a supporting letter from the head of department
to meet the requirements to be considered for an
educational award, the applicant should provide a two
applications will be reviewed by the ECCO 15 – ESMO 34
page Cv and letter explaining the benefit for the applicant
Committee Chairmen and the Editor-in-Chief of EJC.
to attend ECCO 15 – ESMO 34 (in English).
the winner of the ECCO/EJC Young Investigator’s award will
receive a prize of 4000 EUR, free registration for ECCO 15 –
The deadline for receipt of applications is 15 May 2009.
ESMO 34, free accommodation in Berlin for the period of
the conference and reimbursement of travel expenses
an Educational award is worth a free registration and a
free hotel room for a maximum of 4 nights in the period
between 20 - 24 September 2007. (No reimbursement of
travel costs).
Please complete the online application form at:
www.ecco-org.eu

40
general Information
and the opportunity to give an oral presentation of the
Venue
work at ECCO 15 – ESMO 34.
Internationales Congress Centrum Berlin (ICC Berlin)
Messedamm 22
In addition, the winner is expected to write an original
dE-14055 Berlin
paper in English on (part of) the scientific work carried
germany
out. the paper should be based on previously unpublished
www.icc-berlin.de
data and should be written according to the “Instructions
to authors” of EJC, in which it will be published if accepted,
Commercially Sponsored Satellite Symposia
following the usual review process.
ECCO 15 - ESMO 34 Satellite Symposia will take
Deadline for applications: 5 May 2009
place as follows:
applications should be sent to Kaat Cumps, Programme

D Sunday 20/09/09
Co-ordinator via Email: kaat.cumps@ecco-org.eu. Successful
applicants will be notified in the course of July 2009.
11:00 - 12:00
Prime Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 15.2
ECCO – the European CanCer Organisation/ European
Eli Lilly & Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 3
Journal of Cancer (EJC) Young Investigator’s Poster Awards
hospira . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Roof garden Room
Wyeth Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 7
We are also pleased to announce the ECCO/EJC Young
Investigator’s Poster awards, which will be selected and
11:00 - 12:30
presented during ECCO 15 – ESMO 34.
Novartis Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stage Room
13:00 - 16:00
this award is open to young basic scientists and clinical
astraZeneca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .hall 2
oncologists of all disciplines relevant to cancer research.
the award will be given to a young scientist or doctor in the
14:00 - 16:00
field of basic, translational or clinical oncology research for
Pfizer hQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 15.2
original work in cancer research, treatment or care.
Novartis Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stage Room
Merck Sharpe & dohme (MSd) . . . . . . . . . . . . . . Roof garden Room
the following further criteria for application will apply:
helsinn healthcare Sa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 7
– candidates should be junior (within 5 years of
14:00 - 16:30
completion of Phd or specialist training)
f. hoffmann-La Roche Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 3
– candidates should have submitted an abstract
to the congress
17:00 - 19:00
– candidates must indicate that they are young
Merck Serono . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 2
investigators when submitting their abstract
Prime Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 15.2
Novartis Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stage Room
Selection of the award winners will be made by the
Cephalon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Roof garden Room
Scientific Chairmen during the congress.
Bristol-Myers Squibb . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 7
there will be three awards which will be presented during
the Congress.

D monday 21/09/09
18:30 - 20:00
Pfizer hQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 2
f. hoffmann-La Roche Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 3
Bayer Schering Pharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stage Room
Schering-Plough . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Roof garden Room
glaxoSmithKline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 7

D tueSday 22/09/09
18:30 - 20:00
Merck Serono . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 2
Pfizer hQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 3
amgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Stage Room
Schering-Plough . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Roof garden Room
Bristol-Myers Squibb . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 7

ECCO 15 – ESMO 34
41
g
ENER

D WedneSday 23/09/09
Language and Translation
a
L

IN
18:30 - 20:00
the official language of the Congress will be English. No
f
ORM
PharmaMar Sa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 15.2
simultaneous translation will be provided except for the
Merck Serono . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 3
Nursing track, where translation into german will be offerred.
a
t
vifor Pharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Roof garden Room

ION
abraxis Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . hall 7
Lunch and Refreshments
Lunch is included as part of the registration fee and will
for further details, please contact
be provided at the Congress centre (from Monday to
Bruno de Man via Email: bruno.deman@ecco-org.eu or
Wednesday).
by tel: +32 (0) 2 775 02 04.
Official Carrier
Exhibition
the Star alliance Network Members have been appointed
the ECCO 15 – ESMO 34 exhibition represents an
as the Official airline Network for ECCO 15 – ESMO 34.
essential and integral element of the Congress, providing
Participants opting to travel with the Star alliance Network
participants with an excellent platform for networking
will benefit from up to 20% discount on fares.
as well as perfect opportunity to gain further insight into

cutting edge technology, latest healthcare solutions and
Simply call the reservation office of any participating Star
services within the oncology field.
alliance member airline and quote the event code SK11A02.
Registered participants plus one accompanying person
ECCO – the European CanCer Organisation and ESMO – the
travelling to the event are automatically granted a
European Society for Medical Oncology, would gratefully
discount of up to 20%, depending on the class of travel.
like to thank and acknowledge the ECCO 15 – ESMO 34

partners for their support and shared insight. to view the
Participating airlines for this event are: air Canada, aNa,
ECCO 15 – ESMO 34 list of exhibitors, the latest information
asiana, austrian airlines, Lufthansa, Scandinavian airlines,
surrounding the Exhibition and detailed floor plans visit:
Spanair, Swiss, taP air Portugal, and United.*
www.ecco-org.eu (‘Congresses and conferences’,

‘ECCO 15 – ESMO 34’, followed by ‘Exhibition/Sponsorship’).
Booking office information can be found at:
www.staralliance.com/conventionsplus
Entrance is free for all registered participants.

discounts are offered on published business and economy
the exhibition will be open as follows:
class fares, excluding website/internet fares, senior and

D Monday 21 September 10:30-16:30
youth fares, group fares and Round the World fares.
When making your travel plans, please present the

D tuesday 22 September 10:30-16:30
confirmation of your registration as proof of attendance

D Wednesday 23 September 10:30-16:30
and ensure that the Event Code is listed on your ticket.
Companies, publishers and organisations that would
* Please check for updated information on participating
like to participate in the exhibition can download the
airlines for this event at: www.ecco-org.eu
‘Invitation to Industry’ from the Congress website:
www.ecco-org.eu, or contact Bruno de Man via Email:
Passport and Visa
bruno.deman@ecco-org.eu, or by tel: +32 (0) 2 775 02 04.
a valid passport is required for entry into germany. a visa
Insurance
may be required for some countries. for information about
visa and passports contact your local german Embassy at
the organisers do not accept liability for individual medical,
least 3 months prior to your departure to join us in Berlin.
travel or personal insurance and participants are strongly
advised to make their own arrangements regarding health
Transportation
and travel insurance.
Participants registered for the entire duration of the
ECCO 15 – ESMO 34 Congress are entitled to one free public
transport ticket.

42
hotel accommodation & tours
Hotel Accommodation
Adlon Kempinski
Unter den Linden 77, 10117 Berlin, T +49 30 22 610
MCI Berlin Office has been appointed as the official local
Rates incl. german vat and breakfast
housing partner for ECCO 15 – ESMO 34 and is offering hotel
single room: 344 €, double room: 380 €
accommodation, tours and excursions for both groups and
app. distance to ICC Berlin: 7,8 km
individuals.

grand hotel Esplanade
We kindly ask you to contact the appointed local housing
Lützowufer 15, 10785 Berlin, T +49 030 25 47 80
Rates incl. german vat and breakfast single room: 265 €
agent directly for any of these services.
double room: 295 €
app. distance to ICC Berlin: 6,6 km
Please do NOt contact the ECCO 15 – ESMO 34 Secretariat
for this information.
Kempinski hotel Bristol
Kurfürstendamm 27, 10719 Berlin, T +49 30 88 43 40
Rates incl. german vat and breakfast
to check hotel room availability, please contact:
single room: 268 €, double room: 288 €
MCI Berlin Office
app. distance to ICC Berlin: 4,0 km
Markgrafenstrasse 56
Schlosshotel im grunewald
d-10117 Berlin
Brahmstrße 10, 14193 Berlin, T +49 30 89 58 40
tel: +49 (0)30 20 45 931
Rates incl. german vat and breakfast
fax: +49 (0)30 20 45 950
single room: 356 €, double room: 416 €
E-mail: ECCO15ESMO34@mci-group.com
app. distance to ICC Berlin: 3,9 km
www.mci-group.com
Sofitel Berlin gendarmenmarkt
Charlottenstr. 50-52 , 10117 Berlin, T +49 30 20 37 50
The deadline for hotel reservation is 15 August 2009.
Rates incl. german vat and breakfast
after this date accommodation cannot be guaranteed by
single room: 240 EUR, double room: 270 EUR
app. distance to ICC Berlin: 8,8 km
MCI Berlin Office.
The Westin grand
general
Friedrichstr. 158-164, 10117 Berlin, T +49 30 20 270
Rates incl. german vat and breakfast
hotel rooms have been selected according to a number of
single room: 290 €, double room: 349 €
different hotel categories. the prices listed are per room,
app. distance to ICC Berlin: 8,5 km
per night, in EUR (€). the rates include breakfast, service
and vat.
Booking
Abacus Tierpark hotel
Franz-Mett-Str. 3-9, 10319 Berlin, T +49 30 51 620
delegates are encouraged to book online via
Rates incl. german vat and breakfast
www.ecco-org.eu. all rooms are booked on a first
single room: 270 €, double room: 320 €
come first served basis. In the event that the requested
app. distance to ICC Berlin: 24,9 km
hotel is no longer available, the MCI Berlin Office will
Art’otel Berlin Mitte
propose an alternative hotel.
Wallstr. 70-73, 10719 Berlin, T +49 30 24 06 20
Rates incl. german vat and breakfast
this list of hotels is not exhaustive. for further hotel
single room: 231 € double room: 265 €
options, please contact the MCI Berlin Office directly.
app. distance to ICC Berlin: 10,5 km
Arcotel Velvet
Oranienburger Str. 52, 10117 Berlin, T +49 30 27 87 530
Rates incl. german vat and breakfast
single room: 291 €, double room: 399 €
app. distance to ICC Berlin: 9,2 km
Berlin Marriott hotel
Inge-Beisheim-Platz 1, 10785 Berlin, T +49 30 22 00 00
Rates incl. german vat and breakfast
single room: 345 €, double room: 360 €
app. distance to ICC Berlin: 6,6 km

ECCO 15 – ESMO 34
43
Best Western hotel President
h
O
An der Urania 16-18, 10787 Berlin, T +49 30 21 90 30
t
EL
Rates incl. german vat and breakfast
Albrechtshof
a
single room: 155/ 162/172 €, double room: 183 /193/ 203 €
Albrechtstraße 17, 10117 Berlin, T +49 30 30 88 60
C
C
Rates incl. german vat and breakfast
OM
app. distance to ICC Berlin: 5,3 km
single room: 126 €, double room: 165 €
M
O
INN SIDE Premium hotel Berlin
app. distance to ICC Berlin: 8,5 km
d
a
Lange Str. 31, 10243 Berlin, T +49 30 29 30 30
t
ION
Rates incl. german vat and breakfast
Allegra
Albrechtstraße 17, 10117 Berlin, T +49 30 30 88 60

single room: 197 €, double room: 234 €,
&
t
app. distance to ICC Berlin: 11,9 km
Rates incl. german vat and breakfast
OURS
single room: 102 €, double room: 137 €
Mercure hotel Berlin hennigsdorf
app. distance to ICC Berlin: 8,5 km
Fontanestr. 110, 16761 Hennigsdorf, T +49 3302 87 50
Berlin Plaza
Rates incl. german vat and breakfast
Knesebeckstr. 63 Kurfürstendamm, 10719 Berlin, T +49 30 88 41 30
single room: 124 € double room 149 €
Rates incl. german vat and breakfast
app. distance to ICC Berlin: 20,4 km
single room: 139 €, double room: 160 €
app. distance to ICC Berlin: 3,7 km
Mercure hotel Mitte
Luckenwalder Str. 11, 10963 Berlin, T +49 30 51 65 130
Berliner hof
Rates incl. german vat and breakfast
Tauentzienerstr. 8, 10789 Berlin, T +49-30-25 49 50
single room: 126 €, double room: 153 €
Rates incl. german vat and breakfast
app. distance to ICC Berlin: 13,6 km
single room: 115 €, double room: 125 €
app. distance to ICC Berlin: 4,4 km
New Berlin
Petersburger Str. 24, 10249 Berlin, T +49 30 42 02 560
Best Western Euro hotel
Rates incl. german vat and breakfast
Sonnenallee 6, 12047 Berlin, T +49 30 61 38 20
single room: 75 EUR, double room: 102 EUR
Rates incl. german vat and breakfast
app. distance to ICC Berlin: 14,2 km
single room: 136 €, double room: 156 €
app. distance to ICC Berlin: 17,4 km
Nh Berlin Alexanderplatz
Landsberger Allee 26, 10249 Berlin, T +49 30 42 26 130
Comfort hotel lichtenberg
Rates incl. german vat and breakfast
Rhinstr. 159, 10315 Berlin, T +49 30 54 93 50
single room: 205 €, double room: 221 €
Rates incl. german vat and breakfast
app. distance to ICC Berlin: 12,7 km
single room: 105 €, double room: 135 €
app. distance to ICC Berlin: 18,5 km
Nh Berlin Frankfurter Allee
Rathausstr. 2-3, 10367 Berlin, T +49 30 55 75 70
Dietrich Bonhoeffer haus
Rates incl. german vat and breakfast
Ziegelstr. 30, 10117 Berlin, T +49 030 28 46 70
single room: 184 €, double room: 200 €
Rates incl. german vat and breakfast
app. distance to ICC Berlin: 15,2 km
single room: 87 €, double room: 124 €
app. distance to ICC Berlin: 9,5 km
Nh Berlin Treptow
Econtel Berlin Charlottenburg
Spreestr. 14, 10439 Berlin, T +49 30 63 90 30
Sömmeringstr. 24-26, 10589 Berlin, T +49 30 34 68 10
Rates incl. german vat and breakfast
Rates incl. german vat and breakfast
single room: 200 EUR, double room: 216 EUR
single room: 133 €, double room: 146 €
app. distance to ICC Berlin: 21,6 km
app. distance to ICC Berlin: 4,8 km
Park Inn Berlin-Alexanderplatz
Fjord hotel Berlin
Alexanderplatz 8, 10178 Berlin, T +49 30 23 890
Bissingzeile 13, 10785 Berlin, T +49 30 25 47 20
Rates incl. german vat and breakfast
Rates incl. german vat and breakfast
single room: 187 €, double room: 215 €
single room: 89 €, double room: 109 €
app. distance to ICC Berlin: 10,6 km
app. distance to ICC Berlin: 6,9 km
Upstalsboom hotel Friedrichshain
hotel Panorama am Adenauer Platz
Gubener Str. 42, 10243 Berlin, T +49 30 29 37 50
Lewiskamstr. 1, 10629 Berlin, T +49 30 32 90 40
Rates incl. german vat and breakfast
Rates incl. german vat and breakfast
single room: 114 €, double room: 159 €
single room: 95 €, double room: 130 €
app. distance to ICC Berlin: 17,9 km
app. distance to ICC Berlin: 2,5 km

44
Mark Apart hotel
Tours
Lietzenburger Str. 82-84, 10719 Berlin, T +49 30 88 91 20
Berlin City Tour by Bus
Rates incl. german vat and breakfast
single room: 135 €, double room: 165 €
an exciting tour through the past, present and future of
app. distance to ICC Berlin: 3,7 km
Berlin. this bus tour covers the sights and famous memorial
sites, as well as the contradictions and contrasting sides of
Mercure Airport hotel Berlin Tegel
Berlin. You will be guided around the historic city centre,
Kurt-Schumacher-Damm 202, 13405 Berlin, T +49 30 41 060
Rates incl. german vat and breakfast
to both the former and current East and West Berlin, across
single room: 119 €, double room: 134 €
Potsdamer Platz, to government sites old and new, across
app. distance to ICC Berlin: 6,8 km
Stalinist boulevards and modern avenues including the
districts of Kreuzberg and Prenzlauer Berg.
Suitehotel am Potsdamer Platz
Anhalter Str. 2, 10963 Berlin, T +49 30 20 05 60
Duration: approximately 3 hours
Rates incl. german vat and breakfast
Price per person: 36 € (VAT included)
single room: 141 €, double room: 153 €
app. distance to ICC Berlin: 8,7 km
Berlin by Boat
hotel Sylter hof Berlin
this cruise is a definite alternative to a classical bus tour. It
Kurfürstenstr. 114-116 10787 Berlin, T +49 3021 200
will cover the most attractive and fascinating highlights of
Rates incl. german vat and breakfast
the metropolis Berlin. aside from many other locations the
single room: 124 EUR, double room: 179 EUR
cruise will showcase: the german house of Parliament and
app. distance to ICC Berlin: 5,2 km
Bellevue Castle, East Side gallery, Potsdamer Platz,
Sorat hotel Ambassador Berlin
the Nikolai Quarter and the Museum Island.
Bayreuter Str. 42, 10787 Berlin, T +49 30 21 90 20
Rates incl. german vat and breakfast
Duration short tour: 1 hour
single room: 180 €, double room: 200 €
Price per person: 17 € (VAT included)
app. distance to ICC Berlin: 5,3 km
Duration long tour: 3 hours
Tiergarten hotel Berlin
Price per person: 28 € (VAT included)
Alt-Moabit 86, 10559 Berlin, T +49 30 39 98 96
Rates incl. german vat and breakfast
Potsdam & Sanssouci (by bus & on foot)
single room: 87 €, double room: 108 €
app. distance to ICC Berlin: 5,3 km
a Nostalgic future: the Old town of Potsdam. Potsdam is
one of the most beautiful towns in germany. following a
Winter´s hotel Berlin Mitte
visit to Sanssouci Palace you will enjoy a delicious lunch of
Hedemannstr. 11/12, 10969 Berlin, T +49 30 31 98 61 80
typical german cuisine. the guide will then take you to the
Rates incl. german vat and breakfast
Cecilienhof Palace in the New garden where the Potsdam
single room: 181 €, double room: 203 €
Conference took place. the rest of the afternoon is yours to
app. distance to ICC Berlin: 13,4 km
discover the Old town of Potsdam
Winter´s hotel Berlin Messe
at your leisure.
Rudolstädter Str. 42, 10713 Berlin, T +49 30 89 78 30
Duration: 9 hours
Rates incl. german vat and breakfast
single room: 177 €, double room: 189 €
Price per person: 85 € (VAT included)
app. distance to ICC Berlin: 3,7 km
Jewish history in Berlin (on foot)
this tour of Jewish Berlin provides an excellent introduction
to a history so relevant for the Jewish world of today. On
this tour you will encounter Jewish life past and present
in the former Jewish quarter, including the beautiful New
Synagogue from 1866 and the modern Centrum Judaicum.
Duration: 2 hours
Price per person: 20 € (VAT included)

ECCO 15 – ESMO 34
45
ThE WAll (BY FOOT)
Congress Venue
C
ON
Experience the heart of the divided city. discover what is
ICC Berlin - Internationales Congress Centrum
t
a
left of the former death strip between Checkpoint Charlie
Messedamm 22
C
t
US
and Potsdamer Platz. the tour will end at the Brandenburg
d-14055 Berlin
gate and the famous Pariser Platz, which has a totally
germany
different architectural concept than the Potsdamer
tel: +49 30 3038 30 00
Platz. Experiencing these contrasting views of Berlin will
fax: +49 30 3038 30 30
facilitate full appreciation of the traces of the city.
www.icc-berlin.de
Duration: 2 hours
Exhibition & Sponsorship
Price per person: 20 € (VAT included)
for information about sponsorship and exhibition
PLEaSE NOtE: the entrance fee for the Museum at
opportunities please contact Bruno de Man,
Checkpoint Charlie is not included in the price per person.
Email: bruno.deman@ecco-org.eu, tel: +32 2 775 02 04.
for further information and to book tours please contact
Registration
MCI Berlin Office (see below).
for any queries concerning Registration contact:
Riitta Kettunen, Email: riitta.kettunen@ecco-org.eu,
Contact Us
tel: +32 2 775 02 05, or
Abstract Submission
Elisabeth Koeck, Email: elisabeth.koeck@ecco-org.eu,
tel: +32 2 775 29 35.
for more information surrounding abstract Submission please
contact Pat vanhove, Email: pat.vanhove@ecco-org.eu,
tel: +32 2 775 02 42.
Please note : abstracts can only be submitted online at
www.ecco-org.eu
Accommodation & Tours
the MCI Berlin Office is the official local
housing partner for ECCO 15 – ESMO 34 and
is offering hotel accommodation, tours and
excursions for both groups and individuals.

Please contact the MCI Berlin Office directly for any of
these services:
MCI Berlin Office
Markgrafenstrasse 56
d-10117 Berlin
tel: +49 (0)30 20 45 931
fax: +49 (0)30 20 45 950
Email: ECCO15ESMO34@mci-group.com
www.mci-group.com
Congress Secretariat
c/o ECCO – the European CanCer Organisation
avenue E. Mounier 83
B-1200 Brussels
Belgium
tel: +32 2 775 02 01
fax: +32 2 775 02 00 / +32 2 775 02 45
Email: berlin09@ecco-org.eu
www.ecco-org.eu

ECCO A4 Tube Astronaut Ad 28/1/09 12:09 Page 1
Visit our stand to pick up your free copy of Science
Science—covering everything in
the world of science—and beyond.
Join AAAS today and save up to US$70!
Science magazine is truly the inter-
galactic journal of science. Join AAAS
today and start receiving 51 issues of
Science, online access to Science
archives, career and grant information,
exclusive discounts and more. Plus, as
a member of AAAS, you’ll be contribut-
ing to our mission to raise awareness,
improve science education, promote
sound science policy, and support
human rights. AAAS is truly the voice
for scientists—worldwide.
www.aaas.org
www.sciencemag.org
Special offer rates
Professional, Postdoc & Student
U.S.
was US$146.00 now US$99.00
Canada
was US$211.05 now US$136.50*
Mexico
was US$201.00 now US$130.00
All other countries
was US$231.00 now US$160.00
* includes Canadian GST.
Special rates on Science Digital too!
Join AAAS and subscribe to Science today
All countries
was US$146.00 now US$99.00**
**plus 15% VAT to all EU countries
and receive a free poster tube!

Joint eCCo15 - 34th eSmo multidisciplinary Congress
BERLIN, 20-24 SEPtEMBER 2009
REGISTRATION FORM
RE
g
IS
TITLE
t
R
a
t
Prof.
dr.
Mrs.
Ms.
Mr.
ION
f
Last name: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . first name: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ORM
Institute/Company: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . department: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
address: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Postal code: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
City: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Country: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
International tel. number: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . International fax number: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Email: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vat number: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FIELD OF INTEREST
Breast cancer
Oncology in general
Colorectal cancer
Palliative care
Common gynaecological cancers
Pharmacy
Common haematological malignancies
Psychosocial oncology
drug development
Sarcomas
genitourinary cancer
Skin cancer
geriatric oncology
tumours of the central nervous system
head and neck cancer
Upper gastrointestinal cancer
Lung cancer
PLACE OF WORk
Cancer centre
Non for profit organisation
Cancer research centre
Private practice
Contract research organisation
University
general hospital
University hospital
government
Other
Industry
PROFESSION
Basic scientist
Nurse
Clinical trial coordinator
Oncology pharmacist
general physician
Paediatric oncologist
general surgeon
Patient advocate
gynaecologist
Pathologist
haematologist
Radiologist
Lab manager
Radiotherapist
Lab technician
Statistician
Journalist
Student
Medical affairs
Surgical oncologist
Medical oncologist
translational scientist
Neurologist
Urologist
Neuro-oncologist
Other
Neuro-surgeon
PROFESSIONAL MEMBERSHIP
BIg
ECL
ESOP
EUSOMa
EaCR
EONS
ESSO
flims alumni Club
EaNM
EORtC
EStRO
Myeloma Euronet
EaNO
ESgO
Europa donna
OECI
EaU
ESMO
Europa Uomo
SIOP Europe
EBMt
ESO
EUROSKIN
UICC

REGISTRATION FEES
(please tick as appropriate)
Early Rate
Regular Rate
desk Rate
closes 31/03/2009
closes 03/08/2009
as of 04/08/2009
Members*

385 €

825 €

925 €

Non-Members

565 €

895 €

925 €
developing Economies**

100 €

n/a

n/a
Students/Junior Participant ‘in training’***

150 €

150 €

150 €
Patient advocat

200 €

200 €

200 €
Spouse ticket ****

90 €

90 €

90 €
*
EaCR, EONS, ESMO, ESSO, EStRO, SIOPE, EaNO, EaU, EORtC, ESgO, ESO, ESOP, EUSOMa, BIg, EaNM, EBMt, ECL,Europa donna, Europa Uomo,
Euroskin, faC, Myeloma Euronet, OECI, UICC
**
Countries with a Purchasing Power Parity (PPP) per capita of less than US$ 10.000 per annum according to the World Bank listing
available at: www.worldbank.org
*** Confirmation of ‘in training’ status and a letter from the head of department is required.
these documents should be sent to the ECCO 15 – ESMO 34 Congress Secretariat by fax: +32 2 775 02 00
**** this ticket includes access to the Welcome Reception on Sunday, 20 September 2009 as well as a Sightseeing tour of Berlin on Monday, 21
September 2009. N.B.: No access to scientific sessions and the exhibition is granted.
METHOD OF PAyMENT
Paid by credit card (preferred):
Credit card type:
Eurocard/Mastercard
visa
american Express
Card number: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expiry date: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Owner’s name as shown on the card: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Control/CvC-Code: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Please charge the above mentioned credit card for my registration to ECCO 15 – ESMO 34
Remitted by bank transfer:
Owner’s signature:
to the ECCO 15 – 34th ESMO Registration account
account number: 733-034 89 79-03
IBaN: BE21 7330 3489 7903
BIC/SWIft Code: KREdBEBB
KBC Bank, Chaussée de Wavre 1662, B-1160 Brussels, Belgium
Please clearly indicate the name of the participant and “ECCO 15 – ESMO 34 Congress” in all your remittances.
REPLACEMENTS AND CANCELLATIONS
Replacements (= delegate name change) of confirmed registrations are subject to a charge of 75 € per participant. Cancellations of confirmed
registrations are subject to a charge of 100 € per participant provided the cancellation is received before 03 august 2009. for cancellations received
after this date no refunds will be made.
By completing this form I accept the terms and conditions of registration mentioned above.
If posting or faxing please sign and date below.
date: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Signature:

Joint eCCo15 - 34th eSmo multidisciplinary Congress
BERLIN, 20-24 SEPtEMBER 2009
ACCOMMODATION FORM
a
C
C
OMMO
PLEASE COMPLETE AND RETURN TO:
MCI - Berlin Office, Congress Partner gmbh
Email: ECCO15@mci-group.com
d
a
Markgrafenstraße 56
tel: +49 (0)30 20 45 9 0
t
ION
d - 10117 Berlin, germany
fax: +49 (0) 30 20 45 9 50
f
ORM
Please note that the organiser would prefer online bookings at: www.ecco-org.eu
PlEASE COMPlETE BY USINg TYPEWrITEr Or CAPITAl lETTErS
GENERAL DATA – PARTICIPANT
Prof.
dr.
Mr.
Mrs.
home address
clinic address
family Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . first Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Institute/Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Clinic/department . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Street & No . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ZIP Code/City . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Country . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
tel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . fax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
E-Mail . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mobile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GENERAL DATA – ACCOMPANyING PERSON(S)
family Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . first Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
family Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . first Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HOTEL ACCOMMODATION - DEADLINE: 15 AUGUST 2009
room reservations will be confirmed upon hotel and room availability. Rates are per room and night including german vat and service charges,
including breakfast if not stated otherwise. In case of increasing vat or price changes that can’t be influenced by MCI-Berlin Office / CONgRESS
PaRtNER gmbh we have to recalculate. A first night hotel deposit will be charged upon confirmation. All further nights as well as your
incidentals are to be paid directly at the hotel before check-out.
Please find further information about each hotel at: www.ecco-org.eu
No.
hotel
Single
double
No.
hotel
Single
double
room
Room
room
Room
1st night
1st night
1st night
1st night
deposit
deposit
deposit
deposit
13
Mercure hotel Berlin hennigsdorf

€ 124

€ 149
1
adlon Kempinski

€ 344

€ 380
14
Mercure hotel Mitte

€ 126

€ 153
2
Sofitel Berlin gendarmenmarkt

€ 240

€ 270
15
New Berlin

€ 75

€ 102
3
grand hotel Esplanade

€ 265

€ 295
16
Nh Berlin alexanderplatz

€ 205

€ 221
4
Kempinski hotel Bristol

€ 268

€ 288
17
Nh Berlin frankfurter allee

€ 184

€ 200
5
Schlosshotel im grunewald

€ 356

€ 416
18
Nh Berlin treptow

€ 200

€ 216
6
the Westin grand1

€ 290

€ 349
19
Park Inn Berlin-alexanderplatz*

€ 187

€ 215
20
Upstalsboom hotel friedrichshain

€ 114

€ 159
7
abacus tierpark hotel

€ 270

€ 320
8
arcotel velvet

€ 291

€ 399
21
albrechtshof

€ 126

€ 165
9
art’otel Berlin Mitte

€ 231

€ 265
22
allegra

€ 102

€ 137
10
Berlin Marriott hotel

€ 345

€ 360
23
Berlin Plaza

€ 139

€ 160
11
Best Western hotel President

€ 155,-

€ 183
24
Berliner hof

€ 115

€ 125
Business
Business

€ 162,-

€ 193
25
Best Western Euro hotel

€ 136

€ 156
Superior
Superior
26
Comfort hotel Lichtenberg

€ 105

€ 135

€ 172

€ 203
President
President
27
dietrich Bonhoeffer haus

€ 87

€ 124
12
INN SIdE Premium hotel Berlin

€ 197

€ 234
28
Econtel Berlin Charlottenburg

€ 133

€ 146

No.
hotel
Single
double
No.
hotel
Single
double
room
Room
room
Room
1st night
1st night
1st night
1st night
deposit
deposit
deposit
deposit
29
fjord hotel Berlin

€ 89
€ 109
34
hotel Sylter hof Berlin

€ 124
€ 179
30
hotel Panorama am adenauer Platz
€ 95
€ 130
35
Sorat hotel ambassador Berlin

€ 180
€ 200
31
Mark apart hotel

€ 135
€ 165
36
tiergarten hotel Berlin
€ 87
€ 108
32
Mercure airport hotel Berlin tegel

€ 119
€ 134
37
Winter´s hotel Berlin Mitte
€ 181
€ 203
33
Suitehotel am Potsdamer Platz

€ 141
€ 153
38
Winter´s hotel Berlin Messe
€ 177
€ 189
arrival : . . . . . . . . . . . . . . . . . . . . . . . . . . . .
departure: . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
= No. of nights: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Special requests: - realisation depending on availability -
deposit required
covering the first
Nonsmoker
Smoker
facilities for those with special needs
arrival after 06.00 p.m.
night; rest of
Others: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
payment due at hotel

hOtEL dEPOSIt COvERINg thE 1St NIght =
€
METHOD OF PAyMENT:
Payment by credit card
american Express
Eurocard/ Mastercard
visa
Payments by credit card: registration to be
Card Number: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
sent by fax or mail MCI Berlin Office/Congress
Partner GmbH is authorised to charge my
Card holder’s Name: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
credit card upon confirmation of registration
Expiry date: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . / . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
with the GRAND TOTAL amount shown before.
CvC2 / Cvv2 / 4dBC (obligatory): . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Visa/ Euroc.: last three digits above the signature on the back side of the card
AmEx: the four-figure number down on the right on the front side of the card
date: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Signature: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
* Minimum stay is 3 nights in succession at this hotel.
IMPORTANT NOTICE
Yes, registrations by fax will be accepted if payment is made by credit card
I/we accept your general information and conditions.
No, Email and/ or telephone registrations cannot be accepted, nor
I/we agree, that my/ our personal data may be used for this meeting.
duplicates of cheques, purchase orders and/ or electronic bank transfers.
I agree to electronic credit card cashing as stipulated before.
Please understand that confirmations of accommodations booked can only be mailed or faxed on the basis of full pre-payment
date: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Signature: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GENERAL CONDITIONS
hOTElS
deadline for hotel reservation is 15 August 2009. hotel rooms available are limited. Please book your desired hotel as early as possible. If the desired
hotel/category is already fully booked, MCI-Berlin Office/congress partner gmbh reserves the right to arrange accommodation in another hotel/
category. Cancellation of hotel reservations until July 10th, 2009 will lead to forfeiture of € 40 per person. thereafter and until 1 august 2009, 50% of the
booked nights but at least first night rate will be charged. as from 2 august 2009 as well as for no-shows without prior notice, all nights reserved will be
charged.
a fee of € 30 per person will be charged for changes in hotel reservations. the hotel is liable for damages if the reserved room is not made available.
to secure adequate overnight capacities, hotel rooms for the meeting had to be contracted long time in advance. hotels occasionally publish online or
last-minute promotion rates for a limited number of rooms which may vary from the prices contracted for the meeting.
lEgAl CONDITIONS
If a third party takes over the contract from a guest, both parties are liable for payment of the invoices as well as the rebooking fees. the liability
of MCI-Berlin Office/congress partner gmbh for damages – not being injuries to persons – is limited to the triple invoice amount, provided that the
damage is caused neither willfully nor by negligence. MCIBerlin Office/congress partner gmbh is acting as an agent for social program/evening events.
the scientific program is under the organiser’s responsibility. Registration fees are collected by MCI-Berlin Office/congress partner gmbh in the name
of the organiser. these general conditions and all administrative information are to be considered as the legal basis for all reservations. verbal
agreements are not binding, unless confirmed in writing. vouchers/documents will only be distributed upon receipt of full payment. Please pay any
balance in time, as indicated on your invoice. there will be no refund or replacement for lost or unused vouchers/ documents. there will be no right
to lodge damage claims against the organiser in case the realisation of the meeting or parts hereof should be hindered or prevented by unexpected
political or economical reasons or force majeure or should last minute cancellation of speakers or other reasons necessitate program changes. I agree
in the name of all participants registered that my/our datas, for organisational purposes of the meeting, may be used, processed and published
(e.g. within the list of participants). Exclusive Court of Jurisdiction is the Court of Berlin, germany.

Finally, an alternative rises to offer a new
world of opportunities in advanced
Soft Tissue Sarcoma.
Thanks to Yondelis®, a new marine
derived antitumoral agent, and its unique
mechanism of action. It binds to DNA minor
groove interfering with the transcription
processes and DNA repair machinery.1
Yondelis® introduces the concept of Tumour
Control: induces tumour control, delays
disease progression and stabilises the disease.2
Ready to redesign the future
of Soft Tissue Sarcoma?
www.yondelis.com
Yondelis® is indicated for the treatment of patients with
advanced STS, after failure of anthracyclines and ifosfamide,
or in patients who are unsuited to receive these agents.
Please see overleaf for full Prescribing Information.
1. Yondelis® (trabectedin) - Abbreviated Prescribing Information. Please refer to full Summary of Product Characteristics (SPC) when prescribing. 2. Presentation: Yondelis® is presented as a powder for concentrate for solution for infusion. Vial containing trabectedin 0.25 mg powder for concentrate for solution for infusion. Vial containing trabectedin 1 mg
powder for concentrate for solution for infusion. When reconstituted 1 ml of solution contains 0.05 mg of trabectedin. 3. Uses: Advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or where anthracyclines and ifosfamide are not indicated. 4. Dosage and administration: Yondelis® must be administered under the supervision of a physician
experienced in the use of chemotherapy. Its use should be confined to qualified oncologists or other healthcare professionals specialised in the administration of cytotoxic agents. A Yondelis® dose of 1.5 mg/m2 body surface area is administered as an intravenous infusion over 24 hours, once per three‑week cycle. All patients must receive 20 mg of dexamethasone
intravenously 30 minutes prior to Yondelis®. Administration of Yondelis® through a central venous line is strongly recommended. The following criteria must be satisfied prior to each infusion of Yondelis®: absolute neutrophil count ≥1,500/mm3, platelet count ≥100,000/m, haemoglobin ≥9 g/dl, bilirubin ≤ULN, alkaline phosphatase ≤2.5 x ULN, alanine aminotransferase
and aspartate aminotransferase ≤2.5 x ULN, albumin ≥25 g/l, creatinine clearance ≥30 ml/min, creatine phosphokinase ≤2.5 x ULN. Haematological, hepatic and muscle variables should be monitored regularly during treatment. For detailed treatment protocols and rules for dose adjustment and delaying treatment in the presence of abnormal laboratory test results
please consult the SPC. 5. elderly: No dose adjustment specified. 6. children: Yondelis® is not indicated for paediatric use. 7. Hepatic impairment: Special caution is advised and dose adjustments may be necessary in patients with impaired hepatic function, since systemic exposure is probably increased and the risk of hepatotoxicity might be increased. Patients
with elevated bilirubin must not be treated with Yondelis®. 8. Renal impairment: No dose adjustment specified in patients with mild or moderate renal impairment. Contraindicated if creatinine clearance <30 ml/min 9. contraindications: hypersensitivity to trabectedin, concurrent serious or uncontrolled infection, breast-feeding, combination with yellow fever vaccine.
10. Precautions: Caution in presence of hepatic impairment. Patients with clinically relevant liver diseases, such as active chronic hepatitis, must be closely monitored and the dose adjusted if needed. Caution with hepatotoxic drugs and abnormal transaminases, avoid alcohol. Caution in severe renal impairment. Caution in grade 3 or grade 4 neutropenia
and thrombocytopenia (active supportive therapy should be started immediately). Anti-emetic prophylaxis with dexamethasone must be administered to all patients. Yondelis® must not be used in patients with CPK >2.5 ULN. Avoid concomitant treatment with drugs associated with rhabdomyolysis. Avoid CYP3A4 inhibitors. The use of central venous access is
strongly recommended. Combination of trabectedin with phenytoin or live attenuated vaccines is not recommended. Men who are fertile and women of childbearing potential must use effective contraception during and after treatment (3m post use for women and 5m for men). 11. Interactions: The following drugs may interact with trabectedin (consult SPC for
details): ketoconazole, fluconazole, ritonavir, clarithromycin, rifampicin, phenorbarbital, Saint John’s Wort, alcohol, cyclosporine and verapamil. 12. Use in pregnancy and lactation: Trabectedin should not be used during pregnancy unless clearly necessary. Breast‑feeding is contraindicated during treatment and 3 months thereafter. 13. Ability to drive: Fatigue
and/or asthenia have been reported with trabectedin and may affect ability to drive or operate machines. 14. side effects: Most patients (90%) experience adverse reactions to trabectedin: 40% of patients will have grade 3 or grade 4 reactions. Fatal adverse reactions have occurred in about 2% of patients. Common and very common adverse reactions are:
nausea, vomiting, constipation, diarrhoea, anorexia, stomatitis, abdominal pain, dyspepsia, dehydration, decreased appetite, hypokalaemia, leukopenia, neutropenia, thrombocytopenia, anaemia, infection, febrile neutropenia, creatine phosphokinase increased, creatinine increased, albumin decreased, liver function test abnormalities, hyperbilirubinemia, alanine
aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, weight decreased, headache, peripheral sensory neuropathy, dysgeusia, dizziness, paraesthesia, dyspnoea, cough, alopecia, myalgia, arthralgia, back pain, hypotension, flushing, pyrexia, oedema, injection site
reaction, fatigue, asthenia, insomnia. Prescribers should consult the SPC in relation to other side effects. 15. Basic nHs price: Yondelis® 0.25 mg £363 /vial, Yondelis® 1 mg £1,366 /vial. 16. Legal category: POM. 17. Product Licence numbers: EU/1/07/417/001, EU/1/07/417/002 18. Product Licence holder: Pharma Mar, S.A. Avda. de los Reyes 1, Polígono
Industrial La Mina 28770 Colmenar Viejo (Madrid), Spain. 19. further information may be obtained from the UK distributor: IDIS Ltd, IDIS House, Churchfield Road, Weybridge, KT13 8DB. 01932 824 100. 20. Date of preparation: November 2007.
Information about adverse event reporting can be found at www.yellowcard.gov.uk. RefeRences. 1. Carter NJ, et al. Trabectedin. A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007; 67(15): 2257-2276. 2. Morgan JA, et al. Randomized phase II study of trabectedin in patients with
Adverse events should also be reported to IDIS Ltd on 01932 824 100.
liposarcoma and leiomyosarcoma after failure of prior anthracycline and ifosfamide. J Clin Oncol 2007; 25(18S): Abstract 10060.
PrensaYondelis21x29.7ING.indd 1
28/1/09 16:31:46

ADVANCING
IMMUNOTHERAPY
in ONCOLOGY
New Insights are Coming to Light
THE POTENTIAL OF IMMUNOTHERAPY
Modulation of the immune system has the potential to help the body to attack cancer cells – the principle
behind immunotherapy. Some tumours, such as malignant melanoma, are capable of eliciting an immune
response and are candidates for immunotherapy research [1, 2].
UNDERSTANDING T-CELLS
The immune system is under close regulatory control and T-cells have a crucial role in the immune
response [3]. One of the keys to unlocking the potential of immunotherapy is to understand the complexities of
T-cell regulation. Potential targets for immunotherapy include CD-137 [4], PD-1 [5] and CTLA-4 [6] receptors
on T-cells and the CD-40 receptor [7] on antigen-presenting cells.
CTLA-4 – A TARGET FOR IMMUNOTHERAPY RESEARCH
CTLA-4, a receptor expressed on the surface of activated T-cells, is a negative regulator of the T-cell
response [8]. It inhibits production of the costimulatory signal required for T-cell activation and proliferation,
thus placing a brake on the T-cell response.
Blockading CTLA-4 has the potential to remove the brake on T-cell activation, thus enhancing the T-cell
response to tumour cells [8].
This is one area of clinical research that Bristol-Myers Squibb is currently exploring to
help improve clinical outcomes in oncology.
OUR COMMITMENT
Bristol-Myers Squibb has a history of successful innovation in oncology research
and is committed to applying this expertise and resource to advance
immunotherapy in oncology.
Bristol-Myers Squibb – Advancing Immunotherapy in Oncology
REFERENCES
1. Armstrong, A.C., D. Eaton, and J.C. Ewing, Science, medicine, and the future: Cellular immunotherapy for cancer. BMJ,
2001. 323(7324): p. 1289-93. 2. Weiner, L.M., Cancer immunotherapy--the endgame begins. N Engl J Med, 2008.
358(25): p. 2664-5. 3. Pardoll, D., T cells take aim at cancer. Proc Natl Acad Sci U S A, 2002. 99(25): p. 15840-2.
4. Lynch, D.H., The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
Immunol Rev, 2008. 222: p. 277-86. 5. Okazaki, T. and T. Honjo, The PD-1-PD-L pathway in immunological
tolerance. Trends Immunol, 2006. 27(4): p. 195-201. 6. O’Day, S.J., O. Hamid, and W.J. Urba, Targeting
cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and
other malignancies. Cancer, 2007. 110(12): p. 2614-27. 7. Tong, A.W. and M.J. Stone, Prospects
for CD40-directed experimental therapy of human cancer. Cancer Gene Ther, 2003.
10(1): p. 1-13. 8. Cranmer, L.D. and E. Hersh, The role of the CTLA4 blockade in the
treatment of malignant melanoma. Cancer Invest, 2007. 25(7): p. 613-31.
IP-022-2008
ADVANCING IMMUNOTHERAPY
in ONCOLOGYTM
7710885_Advertorial_2_largertext.indd 1
18/12/08 14:18:13

Joint Ecco 15 â 34

Joint Ecco 15 â 34